

CURRICULUM VITAE

Dati personali:

Nome: Valeria Santini

Data di nascita: 12/12/1960

Luogo di nascita: Pisa, Italia.

Cittadinanza: Italiana.

Stato civile: Coniugata, una figlia

- e-mail: valeria.santini@unifi.it

Esperienze formative e titoli di studio :

1979 Maturità classica con il massimo dei voti.

1979-85 Facoltà di Medicina e Chirurgia, Università degli Studi di Firenze.

Laurea in Medicina e Chirurgia il 16/11/1985 con il massimo dei voti e lode

1985-88 Scuola di Specializzazione in Ematologia Clinica e di Laboratorio, Università degli Studi di Firenze. Diploma di Specializzazione con il massimo dei voti e lode ottenuto il 28-10-1988.

Lingue conosciute:

Inglese: 1980 – University of Cambridge- Local examinations syndicate – **C2 Proficiency certificate in English** -

Francese: 1987 –Diploma di conoscenza scritta e parlata– Institut Francais- Florence (voto: eccellente).

Tedesco: 1986- Diploma- lingua scritta e parlata-Zertifikat Deutsch als fremdsprache-Goethe Institut-Rom (voto: discreto)

Olandese: 1993- Diploma- lingua scritta e parlata -Certificaat Nederlands als vreemde taal (Nederlands taalunie- Universitat van Leuven) (livello intermedio).

Esperienze professionali:

1981-85 Allieva Interna nell'Istituto di Patologia Generale dell'Università di Firenze - Tesi sperimentale sulla differenziazione di cellule di eritroleucemia di Friend.

1986-87 Medico frequentatore della Divisione di Ematologia, Università di Firenze e del Laboratorio di Ematologia sperimentale. Studio della chemiosensibilità ai farmaci, cinetica cellulare e crescita in vitro di colonie cellulari nella leucemia mieloide acuta e nella ripresa ematopoietica dopo trapianto di midollo osseo.

1987 Vincitrice Borsa di studio della Lega Italiana per la Lotta contro i Tumori, sezione di Firenze per il follow-up di pazienti oncologici.

1988 Vincitrice di una Borsa di Studio Europea del Soroptimist International Club per studi nel Cell Culture Laboratory of Dr Daniel den Hoed Cancer Center, Rotterdam, Paesi Bassi; supervisione scientifica del Dr. Bob Löwenberg.

Dal 1-12-1988 al 1-6- 1989 Assunta come ricercatore del Cell Culture Laboratory, Dr Daniel Den Hoed Cancer Center, Rotterdam, Paesi Bassi.

1989 Vincitrice di una Borsa di Studio Nazionale dell'Associazione Italiana per la Ricerca sul Cancro (AIRC).

1990 Vincitrice dell' European Organization for the Research and Treatment of Cancer (EORTC) Fellowship, in collaborazione con il Dr Daniel den Hoed Cancer Center e con Institute of Hematology, Erasmus University, Rotterdam, Paesi Bassi.

1992-94 Medico frequentatore della Divisione di Ematologia e del Laboratorio, Università degli Studi di Firenze. Allestisce un servizio di diagnostica molecolare per il follow up della leucemia mieloide cronica pre- e post-trapianto allogenico, e di altre patologie ematologiche, in collaborazione con il Prof. G. Saglio, presso il Laboratorio di Medicina ed Oncologia Molecolare, Dipartimento di Scienze Biomediche ed Oncologia Umana, Università di Torino.

1994 Ricercatore Universitario presso la Cattedra di Ematologia, Università degli Studi di Firenze.

1999 Visiting Scientist -MD Anderson Cancer Center Houston -Leukemia Unit

dal 1-11-2000 ad oggi Professore di seconda fascia- settore scientifico disciplinare MED/015 Università degli Studi di Firenze.

Attività didattica

1997-98 Affidamento ai sensi dell'art 12 della legge 341/90 insegnamento nel Corso di laurea Medicina e Chirurgia - Ematologia per il Corso Integrato di Malattie del Sangue

1997-2002 Docente nel DU Tecnico sanitario di laboratorio Biomedico, SSD F04B Patologia Clinica. Corso integrato di tecniche di patologia Clinica e immunoematologia. Sedi di Firenze e Figline Valdarno.

1997/98 Insegnamento di Ematologia per il Corso integrato di Malattie del Sangue

1998-1999 Affidamento ai sensi dell'art 12 della legge 341/90 insegnamento settore ex-F07G, Malattie del sangue nel Corso di Laurea Medicina e Chirurgi, nelle sedi di Firenze e di Prato.

2001-ad oggi Docente coordinatore nel Corso di Laurea-Tecniche di laboratorio biomedico (abilitante alla professione sanitaria di tecnico di laboratorio biomedico), Università di Firenze, nell'insegnamento Tecniche diagnostiche di patologia clinica e immunoematologia, modulo Malattie del Sangue.

2013- ad oggi Docente coordinatore modulo Malattie del Sangue nell'insegnamento Infermieristica clinica specialistica e coordinatore del corso integrato. Corso di Laurea triennale in Infermieristica abilitante alla professione, Università di Firenze per la Sede di Prato.

2007- 2011 Insegnamento modulo Malattie del Sangue nel corso integrato di Medicina nella Corso di Laurea Triennale (DM 509/99) in Igiene Dentale (abilitante alla professione sanitaria di igienista dentale).

2020/2021- Vice Presidente Corso di Laurea in infermieristica abilitante alla professione per la Sede di Prato.

Incarico di Docenza presso le seguenti Scuole di specializzazione della Università di Firenze per il modulo Malattie del sangue : 1998/1999- Gastroenterologia ed endoscopia digestiva I e II, 2013-2016 Medicina d'emergenza e urgenza, 2013-2017 Endocrinologia e malattie del ricambio, 2016-2023- Chirurgia orale, 2014-2021 Farmacologia e Tossicologia Clinica, 2014- 2015 Malattie dell'apparato respiratorio, 2019-2023 - Medicina nucleare.

1994 ad oggi Affidamento attività didattica Scuola di Specializzazione in Ematologia , Università degli Studi di Firenze.

2015/16- ad oggi Docente Università degli Studi di SIENA Titolo: "Dottorato di ricerca in genetica, oncologia e medicina clinica (GENOMECC)"

2007-2012 Docente Master "Malattie metaboliche dell'osso: dal gene alla cura" Università di Firenze- Responsabile Prof L. Brandi

2022-2023 Docente Master "Malattie Rare" Università di Firenze- Responsabile Dr C. Scaletti.

2010 Membro della Commissione della Tesi di Dottorato Europeo (candidata A.B.V.M) Departamento de Genetica, Facultad de Biología, Universidad de Valencia, Hospital universitario La Fe- Servicio de Hematología. Spagna. *Regulation epigenetica de la via wnt por metilacion aberrante de sus genes represores en la leucemia mieloide aguda*

2014 Membro Rapporteur della Commissione della Tesi di Dottorato Europeo (candidata P.G.) Université Paris Diderot (Paris 7) Sorbonne Paris Cité- Ecole Doctorale biologie et biotechnologie -Hematologie et Oncologie-UMR-S1131, Institut Universitaire d'Hematologie, Francia. Eurocancer Marie Curie fellowship in cancer stem cell research. *Le ciblage des cellules souches leucémiques dans deux modèles murins de cancer myéloïdes.*

2024 Membro della Commissione della Tesi di Dottorato Europeo (candidata U.S.A.S.) Erasmus University Rotterdam, The Netherlands. PhD thesis: Intrinsic and Extrinsic Mechanisms of Clonal Expansion in Del(5q) MDS.

1994-ad oggi Relatrice di tesi di Laurea Corsi di Laurea in Medicina e Chirurgia, Tecnici di Laboratorio Biomedico, Infermieristica, Biologia, Biotecnologie mediche e farmaceutiche della Università di Firenze.

Relatrice di tesi di Specializzazione in Ematologia della Università di Firenze e Università di Pisa.

Presentazioni scientifiche e seminari

Oltre 150 presentazioni come relatrice invitata in meeting scientifici nazionali ed internazionali.

Attività assistenziale

05/04/1995 Ruolo in Dirigenza sanitaria medica – assistente ospedaliero nell'ambito della convenzione Università di Firenze- USL 10/D (poi Azienda ospedaliera Careggi)

1-11-1995 Qualifica di Aiuto Corresponsabile di Ematologia

1-11-1997 ad oggi Qualifica di dirigente medico di I livello. Attività clinica nel reparto di Ematologia con Trapianti, Azienda Ospedaliera Careggi e Università degli Studi di Firenze.

1998-2001 Posizione funzionale lettera H- attività sezione di degenza e tecniche di biologia molecolare- UO Ematologia- (direttore Prof Rossi Ferrini).

2001-2018 Posizione funzionale lettera D-responsabile di settore organizzativo gestionale interno UO Ematologia- malattie mieloproliferative croniche (direttore Prof Rossi Ferrini). responsabile del programma clinico sindromi mielodisplastiche- SOD Ematologia -AOUC- Firenze

2001-2010 responsabile del programma clinico e diagnostica leucemia mieloide cronica della Unità Funzionale di Ematologia; AOU Careggi, Firenze.

7-9-2018-oggi Responsabile Unità Dipartimentale Sindromi mielodiplastiche (MDS Unit), DAE Oncologico- AOU Careggi.

1995-ad oggi attività assistenziale reparto degenza e ambulatorio SOD Ematologia AUC Firenze. Turni di guardia in presenza per SOD Ematologia-AOUC-Firenze e SOD Terapie cellulari e medicina trasfusionale - Opzione tempo pieno e libera professione intra moenia.

2002 and oggi Principal Investigator responsabile di 73 Studi clinici sperimentali (nazionali) e internazionali: 8 studi di fase I/II, 20 studi di fase II, 45 studi di fase III, 6 studi osservazionali per pazienti con sindromi mielodisplastiche, leucemia mieloide dell'anziano e leucemia mieloide cronica.

2015 Giudizio altamente positivo (no findings) dopo l'audit FDA per la conduzione dello studio cc-5013-MDS-005.

2023 Giudizio positivo dopo l'audit FDA per la conduzione dello studio Imerge-MDS.

Conseguimento di premi e riconoscimenti nazionali e internazionali per attività di ricerca:

1995- Premio migliore comunicazione orale 35° Congresso Società Italiana di Ematologia

1997- Premio migliore comunicazione orale Fondazione catanese per lo studio e la cura della malattie del sangue. 36° Congresso Società Italiana di Ematologia

2005- Relatrice invitata Grand Round lecture John Hopkins University, Baltimore US

2007 American Society of Clinical Oncology (ASCO) Relatrice invitata per la sessione educativa sulle sindromi mielodisplastiche

2008 Review article Award on anticancer chemotherapy- Journal of Chemotherapy

2012 American Society of Hematology (ASH) Relatrice invitata per la sessione educativa sulle sindromi mielodisplastiche

2015 - Relatrice invitata Grand Rounds- YALE University New Haven, US- Lecture title: *Orienteering in the labyrinth of myelodysplastic syndromes.*

2016- Premio Leadership in Science – AA& MDS International Foundation

2016 European Hematology Association (EHA) Relatrice invitata per la sessione educativa sulle sindromi mielodisplastiche

2016 American Society of Hematology (ASH) Chair della sessione e Relatrice invitata per la sessione educativa sulle sindromi mielodisplastiche

2017 - Relatrice invitata Grand Round Vanderbilt -Ingram Cancer Center -myeloid working group- Vanderbilt University – Nashville US- lecture title "*What is new in LR MDS? From biology to treatment.*"

2013 e 2015 Relatrice sessioni educative del Congresso Nazionale (Società Italiana di Ematologia) SIE

2006 Relatrice simposio istituzionale Congresso Nazionale (Società Italiana di Ematologia Sperimentale) SIES

2017 Relatrice Simposio Presidenziale Congresso Nazionale (Società Italiana di Ematologia) SIE.

2020- European Hematology Association (EHA) Meeting; Chair: Education session "Understanding disease pathophysiology for better treatment in myelodysplastic syndromes (MDS)".

2021- European Hematology Association (EHA) Meeting; Chair: Hematology-in-focus session "Near future in HR-MDS treatment"

2023- Relatrice invitata MDS Foundation International symposium -sessione plenaria

2023- Relatrice invitata American Society of Hematology (ASH) nella Spotlight Educational session.

2024- Chair e relatrice alla sessione educativa della American Society for Clinical Oncology (ASCO) TP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates.

Annoverata nella pubblicazione *“Updated science-wide author databases of standardized citation indicators”* Ioannidis et al., 2020 PLOS Biology che include dati di tutti gli scienziati che sono tra i top 100,000 in tutti i campi, secondo il *composite citation index* (career-long citation impact up fino alla fine del 2019 e citation impact solo nell’anno 2019).

Organizzazione, direzione e coordinamento di centri o gruppi di ricerca nazionali e internazionali o partecipazione agli stessi e altre attività di ricerca

Attuali e continuative:

Direzione Laboratorio di Ricerca Sindromi Mielodisplastiche- Università di Firenze (personale a contratto : 2 PhD con assegno di ricerca, 3 dottorandi, 2 assegnisti, 3 medici specializzandi afferenti)

Responsabile scientifico Unità di ricerca Progetti PRIN-MIUR 1998, 1999, 2001, 2005 (vedi lista grant ottenuti)

Direzione scientifica Fondazione Italiana sindromi mielodisplastiche (FISIM) per ricerche cliniche e precliniche su scala nazionale

Direzione WP-2 progetto Europeo Harmony per sindromi mielodisplastiche (vedi lista grant ottenuti)

Collaborazione progetto Europeo medicina molecolare Genomed4All.

Collaborazione come Responsabile Gruppo Italiano nell’ European myelodysplastic cooperative group (EMSCO) per ricerche cliniche ed eventi di educazione su MDS.

Partner dell’ International working group for MDS (IWG-M). Collaborazione di ricerca per la classificazione e la prognosi delle sindromi mielodisplastiche

Partner dell’ International working group for immune monitoring of MDS (i4MDS). Collaborazione di ricerca per la classificazione immunologica delle sindromi mielodisplastiche

Partner dell’ International consortium for MDS (icMDS). Collaborazione di ricerca per la terapia delle sindromi mielodisplastiche

Collaborazione di ricerca per la classificazione e la prognosi delle sindromi mielodisplastiche/ mieloproliferative - MDS Foundation MDS/MPN IWG working party.

European School of Hematology (ESH) membro del comitato scientifico.

European Leukemia Net (ELN) collaborazione a gruppo collaborativo -progetti di ricerca su MDS

European Hematology Association – Membro dell' Executive Board del Working party MDS e EHA Guidelines project su "Cytopenias in the elderly".

EurobloodNet, sviluppo nel registro malattie rare della sezione delle neoplasie mieloidi (MDS) in collaborazione con Prof P. Fenaux

Collaborazione a progetti di ricerca clinica nazionali del gruppo cooperatore GIMEMA

Collaborazione scientifica con il gruppo latino americano di studio delle mielodisplasie (GLAM)

Collaborazione con EORTC Anaemia Working Party, European Society of Medical Oncology (ESMO). Organizzazione di Corsi residenziali e redazione di line guida.

Collaborazione con International Society of Geriatric Oncology (SIOG) – Redazione linee guida per leucemia acuta dell'anziano (in corso).

Collaborazione scientifica con Groupe Francophone des myelodisplasies (GFM).

Collaborazione scientifica con Grupo español de síndromes mielodisplásicos (GESMD).

2013 Collaborazione come Principal investigator allo studio clinico con IRCCS Reggio Emilia (Dr Apolone) su progetto mini MDS-GA Validazione psicométrica e clinica di uno strumento breve per la valutazione del paziente onco-ematologico anziano

Collaborazione (dal 2005) nei workshop biennali di Clinical Translation of epigenetics in cancer therapy, organizzati da Yale School of Medicine, MDAnderson Cancer Center, University of Miami.

1986-1994 Collabora all'unità operativa CNR, progetto finalizzato "Oncologia".

1987-97 Collaborazione ai progetti cofinanziamento MURST 40% attribuiti alla Cattedra di Ematologia, Università degli Studi di Firenze.

Fondi di ricerca

1998 Responsabile Scientifico dell'Unità di ricerca (Università di Firenze) nel Progetto cofinanziamento PRIN- MIUR (coordinatore F.Mandelli) *Secondi messaggeri nella*

maturazione ed apoptosi delle cellule di leucemia mieloide acuta. Possibile bersaglio terapeutico ?

1999 Partecipante al Programma di ricerca (Università di Firenze) nel Progetto cofinanziamento PRIN- MIUR (coordinatore G.Saglio) *Ipermetilazione del DNA nella progressione di malattia e nel follow up della leucemia mieloide cronica*

2001 Responsabile Scientifico dell'Unità di ricerca (Università di Firenze) nel Progetto cofinanziamento PRIN- MIUR (coordinatore M. Bacarani) *Ruolo dell'ipossia e dell'oncogene fes nel controllo della crescita e nella resistenza al trattamento nella leucemia mieloide cronica.*

2005- Responsabile Scientifico dell'Unità di ricerca (Università di Firenze) nel Progetto cofinanziamento PRIN- MIUR (coordinatore G.Leone) *Profilo molecolare delle alterazioni epigenetiche in mielodisplasie ad alto rischio: azione specifica di diversi inibitori delle istone deacetilasi*

2009- Bando Salute Regione Toscana- Responsabile scientifico del progetto *MDS proteomics: clinical significance of modifications in protein expression in bone marrow CD34+ cells from MDS patients.*

2010-2016- Responsabile scientifico del Progetto MDS finanziato con contributo annuale alla ricerca da Celgene.

2011- Responsabile scientifico- Grant Ente Cassa di Risparmio di Firenze- *Analisi modificazioni funzionali e molecolari in cellule midollari mielodisplastiche prima e dopo trattamento con azacitidina.*

2013 Leukemia and Lymphoma Society (LLS) Translational Research grant TRP-6016-14

2013- Grant Ente Cassa di Risparmio di Firenze- *Alterazioni molecolari nella risposta ad azacitidina in pazienti con MDS.*

2015 Responsabile scientifico AIRC -Investigator Grant - IG 2015 biennale- # 16861- Title: *Mechanisms of resistance to hypomethylating agents in myelodysplastic syndromes.*

2016- ad oggi Coordinatore internazionale-key opinion leader MDS working party-2 del progetto europeo Horizon2020 Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in Hematology - Sofia ref.: 116026 "HARMONY European Network of Excellence". H2020-JTI-IMI2-2015-06-two-stage. IMI2

2016- Responsabile scientifico Grant Fondazione Cassa di Risparmio Pistoia e Pescia *"Meccanismi di resistenza all'agente ipometilante Azacitina in pazienti affetti da Sindrome Mielodisplastica"*

2019 – Responsabile Grant Ente Cassa di Risparmio di Firenze- *Meccanismi di resistenza agli agenti ipometilanti nelle sindromi mielodisplastiche*

2020- 2023 Coordinatore internazionale WP-2 MDS del progetto europeo Horizon 2020 "HARMONY PLUS European Network of Excellence". healthcare alliance for resourceful medicines offensive against neoplasms in hematology – PLUS- IMI2 - Call H2020-JTI-IMI2-19, Grant agreement number 945406.

2021- 2024 Responsabile scientifico del Progetto 8 per European project Marie Skłodowska Curie Action Innovative Training Networks (ITN ETN) Exploring cell to cell heterogeneity and exploiting epigenetic regulation for the interception of myeloid disease cells " INTERCEPT MDS GA n. 953407.

2022-2027 Responsabile e coordinatrice AIRC quinquennale - Individual Grant - IG 2021-PROJECT NUMBER: 26537. Titolo: Senectus ipsa morbus est ?- How to distinguish inflammaging from clonal myelodysplastic syndromes

2023 Collaborante a PNRR – Progetto THE-Spoke3.

Cariche/ attività istituzionali, organizzative e di servizio svolte presso Istituzioni di alta formazione e di ricerca nazionale e internazionale

2002-2004 -Vice-presidente Societa' Italiana Ematologia sperimentale, Membro consiglio scientifico Societa' Italiana Ematologia Sperimentale (SIES)

2006-2010 -Membro del Consiglio direttivo Societa' Italiana Ematologia (SIE) per due mandati.

2001- ad oggi- Membro Consiglio Scientifico del Centro Interdipartimentale di Spettrometria di Massa – CISM- Università degli Studi di Firenze

2010 –data attuale -Membro Medical advisory board of the Aplastic anemia and myelodysplastic syndromes International Foundation (AA & MDS IF).

2015-2017 -Membro dello Scientific Committee European School of Hematology (ESH) con pianificazione a approvazione del programma scientifico. Responsabile scientifico di ESH Translational Research Conferences- Erythropoiesis Control and Ineffective Erythropoiesis : from bench to bedside (2019 e 2021). Faculty di ESH translational research conferences on Myelodysplastic Syndromes (MDS) dal 2008 al 2022.

2015-2019- Membro International Committee Celgene's Hematology Awards

2011-2017- Co-chair GIMEMA working party per le sindromi mielodisplastiche

2017-2020- Membro del Board GIMEMA working party per le sindromi mielodisplastiche

2017- Faculty del corso Tutorial EHA- AHA (Armenian Society of Hematology).

2018- Faculty dell' EHA-KSH Joint Symposium nell' ambito di Korean Society of Hematology (KSH) International Conference e Annual Meeting.

2015-2020 - Presidente Fondazione Italiana sindromi mielodisplastiche (FISMonlus, poi FISiMets)

2020-data attuale- Presidente Comitato Scientifico Fondazione Italiana sindromi mielodisplastiche (FISiMets)

2018 ad oggi – Membro Executive Board EHA working party MDS.

2016 -ad oggi Membro ERN-EurobloodNet; dal 2020 membro del Clinical Patient Management System (CPMS) Eurobloodnet

2014- ad oggi Membro di Steering Committee, Education Committee and Ambassador program della Society of Hematologic Oncology (SOHO)

2019 Nomination for ASH myeloid neoplasia committee service.

Direzione o partecipazione a comitati editoriali di riviste

2017-2020 Membro dell'editorial Board di *Blood- Journal of the American Society of Hematology* (IF 22.11)

2021- Membro dell' Editorial Board di *Blood Reviews* (IF 8.25)

2021- Membro dell' Editorial Board di *Cells* (IF 4.89)

2020- ad oggi Membro dell' Editorial Board di *Hemato* – (MDPI Journal)

2014-2016 Associate Editor *Drugs Cell Therapies in Hematology*

2015- Section Editor *for Seminars in Hematology*

2023- Membro dell'editorial board di *Leukemia* (IF

Appartenenza a Società scientifiche

Società italiana di ematologia (SIE)

Società italiana di ematologia sperimentale (SIES)

American Society of Hematology (ASH)
European Hematology Association (EHA)
Society of Hematologic Oncology (SOHO)

Honorary membership:

Sociedad Argentina de Hematologia
Armenian Society of Hematology

Attività di terza missione e conseguimento della titolarità di brevetti

Brevetto DEC 2014 : PATENT Attorney Docket No.: UM-34148/US-1/PRO US Application No. 62/097,279 . BIOMARKERS FOR PREDICTING RESPONSIVENESS TO DECITABINE THERAPY

Altre attività di rilevanza scientifica:

a) Revisione di progetti di ricerca internazionali

- dal 2016 Annual Reviewer dei progetti presentati per Research grant - Aplastic anemia and MDS International Foundation
- Institut National du Cancer INCa Boulogne Billacourt, cedex, Francia– Membro della commissione per Project evaluation per grant for Translational Cancer Research
- Membro della commissione per Project evaluation per grant for Fundamental Research-- Dutch Cancer Society- Alpe d'HuZes consortium -Experimental Hematology e Molecular Biology
- Membro della commissione per Project evaluation per grant for Lise Meitner Program for Austrian Science Fund.
- Membro della commissione per Project evaluation per IIS spagnoli. Proyectos integrados de excelencia – Strategic action for health research– integrated project of excellence. Institut de salud Carlos III.
- Membro della commissione per Project evaluation per grant Czech Health Research Council – AZV-CR -established by Ministry of Health of the Czech Republic.
- Membro della commissione per Project evaluation per grant Swiss Cancer Research Foundation and Swiss Cancer League.
- Membro della commissione di valutazione Deutsche Forschungsgemeinschaft (DFG), Schwerpunktprogramm 1(SPP) 1463 „Epigenetic regulation of normal hematopoiesis and its dysregulation in myeloid neoplasia” 2013-2016.

- Membro dello Scientific Evaluation Committee for High-Risk High-Gain call for proposals against cancers with poor prognosis- French National Cancer Institute 2021.

b) Revisione di manoscritti presentati a riviste internazionali

Attività certificate di peer reviewer per 43 riviste internazionali tra cui: Blood, New England Journal of Medicine, Nature Medicine, Journal of Clinical Oncology, Lancet Oncology, Lancet Hematology, Cancer Research, Leukemia, American Journal of Hematology, Blood Advances, Blood reviews ed altre con minore IF.

Revisore Abstract per congressi annuali di American Society of Hematology (ASH), European Hematology association (EHA), SIE, SIES, SOHO.

c) Pubblicazioni di linee guida di diagnosi e trattamento

Linee guida SIE SIES GITMO per sindromi mielodisplastiche Leuk Res 2010

Linee guida SIE SIES GITMO per trattamento CMML Haematologica 2013

Linee guida EHA/ELN per CMML Hemasphere 2018

Linee guida IWG per criteri di risposta ematologica in MDS – Blood 2019

Linee Guida ESMO per diagnosi e trattamento MDS Ann Oncol 2014 e Ann Oncol 2021

Linee guida ESMO per trattamento della anemia e carenza ferro in neoplasie Ann Oncol 2018

Linee guida SIOG per il trattamento della leucemia mieloide acuta dell'anziano (in preparazione)

d) attività di membro di *data safety monitoring board* (DMSB) di studi clinici internazionali

Studio Apollo-trial EudraCT-No 2015-001151-68: A randomized Phase III trial to compare arsenic trioxide (TO) combined to ATRA and idarubicin versus standard ATRA and anthracyclines-based chemotherapy (AIDA regimen) for patients with newly diagnosed , high risk acute promyelocytic leukemia- Sponsor : Technische Universitat Dresden- Ruolo di coordinator del DMSB

Studio Volasertib: Boehringer-Ingelheim trial 1230.33, A Phase I, open label, dose escalation (3 +3) international clinical study of volasertib combined with azacytidine in 85 patients with MDS and CMML ineligible for HSCT.

f) Public engagement.

2007 Organizzazione della giornata per pazienti MDS nell'ambito del convegno MDS Foundation – Firenze

2011-2013 Presidente del Soroptimist Club Firenze Due, club di servizio per la promozione delle donne

2017 ad oggi- Membro del consiglio scientifico AIPASIM, Associazione Italiana pazienti con sindrome mielodisplastica. Presenza ad incontri con pazienti (50-100 partecipanti) a Firenze e Milano, in collaborazione con Associazione Italiana Leucemie- AIL

Documentata divulgazione scientifica su MDS e leucemie sul VJHemOnc MDS Channel . 6676 Visualizzazioni video.

2016-2020 Membro della Commissione pari opportunità dell'Ordine dei Medici di Firenze

2020- Webinar Molecular Diagnosis of MDS, sul sito EuroBloodNet

2020 Webinar AAMDSIF Global Update on COVID-19 for patients- Aplastic anemia & MDS International Foundation (AA&MDS).

2021 Virtual Broadcast MDS Session with VJHemOnc - Women in Science .

2021- Accademico d'onore della Accademia delle arti del disegno (fondata 1563).

Pubblicazioni di Capitoli di Libri:

Santini V. e Rossi Ferrini P. Capitolo XIII: Malattie del Sangue e degli organi Emopoietici pgg 1573-1681 In: Medicina Interna, a cura di Bartoli, Gensini, Laffi, Lucivero, Trimarco , edizioni Idelson -Gnocchi - Napoli 2003.

Santini V. Chapter 4. Supportive therapy for ineffective haematopoiesis in MDS and AML pgg 104-110 . In : MDS and Acute Myeloid Leukemias: A Biological and Therapeutical Continuum, a cura di M. Luebbert, edizioni UNI-MED Verlag AG Bremen - London – Boston 2013

Santini V. e MT Voso . Capitolo 17: Sindromi mielodisplastiche pgg 215-223; in: Ematologia per Medicina, Scienze Biologiche, Biotecnologie mediche, a cura di N.Giuliani e A.Olivieri. Edizioni Idelson-Gnocchi – Napoli 2020

Santini V. Capitoli 4.3 e 4.4 Sindromi mielodisplastiche e sindromi mielodisplastiche/mieloproliferative, pgg 184-198 in : Corso di Malattie del Sangue e degli organi emolinfopoietici, a cura di S.Tura, M. Cavo, PL Zinzani (A. Broccoli). Edizioni Società Editrice Esculapio, Bologna 2020.

Santini V. Chapter 33 "Novel Strategies to Manage Cytopenia in Low-Risk MDS" In: Harinder Gill and Yok-Lam Kwong (Eds): Pathogenesis and Treatment of Leukemia, Springer Nature, 2023.

Lista Pubblicazioni su riviste internazionali con peer-review:

Della Porta MGD, Garcia-Manero G, **Santini V**, et al. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial. *Lancet Haematol.* 2024 Jul 19:S2352-3026(24)00203-5. doi: 10.1016/S2352-3026(24)00203-5. Epub ahead of print. PMID: 39038479.

Attardi E, Tiberi L, Mattiuz G, ..., **Santini V**. Prospective genetic germline evaluation in a consecutive group of adult patients aged <60 years with myelodysplastic syndromes. *Hemasphere.* 2024 Jul 15;8(7):e112. doi: 10.1002/hem3.112. PMID: 39015540; PMCID: PMC11250510. (**corresponding author**)

Bernard E, Hasserjian RP, Greenberg PL, **Santini V** ...
Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications. *Blood.* 2024 Jul 3:blood.2023023727. doi: 10.1182/blood.2023023727. Epub ahead of print. PMID: 38958467.

D'Amico S, Dall'Olio L, Rollo C, **Santini V**, MOSAIC: An Artificial Intelligence-Based Framework for Multimodal Analysis, Classification, and Personalized Prognostic Assessment in Rare Cancers. *JCO Clin Cancer Inform.* 2024 Jun;8:e2400008. doi: 10.1200/CCI.24.00008. PMID: 38875514.

Effiace F, Buckstein R, Abel GA,.... **Santini V**, Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).

Hemasphere. 2024 May 21;8(5):e69. doi: 10.1002/hem3.69. PMID: 38774655; PMCID: PMC11106800.

Santini V, Stahl M, Sallman DA. *TP53* Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates. Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e432650. doi: 10.1200/EDBK_432650. PMID: 38768424.

Tentori CA, Zhao LP, Tinterri B, **Santini V**, ; i4MDS consortium. Immune-monitoring myelodysplastic neoplasms: Recommendations from the i4MDS consortium. Hemasphere. 2024 May 15;8(5):e64. doi: 10.1002/hem3.64. PMID: 38756352; PMCID: PMC11096644.

Tentori CA, Gregorio C, Robin M, ... **Santini V**.... Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes. J Clin Oncol. 2024 May 9;JCO2302175. doi: 10.1200/JCO.23.02175. Epub ahead of print. PMID: 38723212.

Sirenko M, Bernard E, Creignou M.... **Santini V**...
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes. Blood. 2024 Apr 30;blood.2023023723. doi: 10.1182/blood.2023023723. Epub ahead of print. PMID: 38687605.

Winter S, Schneider M, Oelschlaegel U, ... **Santini V**,... Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DR monocytes in lower-risk myelodysplastic neoplasms. Leukemia. 2024 Jun;38(6):1427-1431. doi: 10.1038/s41375-024-02249-z. Epub 2024 Apr 17. PMID: 38632316; PMCID: PMC11147767.

Onida F, Gagelmann N, Chalandon Y, ... **Santini V**, ... Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee. *Blood*. 2024 May 30;143(22):2227-2244. doi: 10.1182/blood.2023023476. PMID: 38493484.

Zeidan AM, Ando K, Rauzy O, **Santini V**... Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo- controlled, phase 2 trial. *Lancet Haematol*. 2024 Jan;11(1):e38-e50. 10.1016/S2352-3026(23)00333-2. Epub 2023 Dec 5. Erratum in: *Lancet Haematol*. 2024 Mar;11(3):e181. doi: 10.1016/S2352-3026(24)00035-8. PMID: 38065203

Platzbecker U, **Santini V**, Fenaux P, et al. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2024 Jan 20;403(10423):249-260. doi: 10.1016/S0140-6736(23)01724-5. Epub 2023 Dec 1. Erratum in: *Lancet*. 2024 Jan 20;403(10423):248. doi: 10.1016/S0140-6736(24)00057-6. PMID: 38048786.

Roncareggi S, Girardi K, Fioredda F, **Santini V**, ... A Nationwide Study of GATA2 Deficiency in Italy Reveals Novel Symptoms and Genotype-phenotype Association. *J Clin Immunol*. 2023 Nov;43(8):2192-2207. doi: 10.1007/s10875-023-01583-8. Epub 2023 Oct 14. PMID: 37837580.

Platzbecker U, **Santini V**, Komrokji RS, et al . Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts. *Leukemia*. 2023 Nov;37(11):2314-2318. doi: 10.1038/s41375-023-02031-7. Epub 2023 Sep 26. PMID: 37752285; PMCID: PMC10624606.

Extermann M, Artz A, Rebollo MA, **Santini V**,; SIOG. Treating acute myelogenous leukemia in patients aged 70 and above: Recommendations from the International Society of Geriatric Oncology (SIOG). *J Geriatr Oncol*. 2024 Mar;15(2):101626. doi: 10.1016/j.jgo.2023.101626. Epub 2023 Sep 21. PMID: 37741771

Stahl M, Bewersdorf JP, Xie Z, ... **Santini V**, ... Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). *Blood Rev*. 2023 Nov;62:101128. doi: 10.1016/j.blre.2023.101128. Epub 2023 Aug 19. PMID: 37704469.

D'Amico S, Dall'Olio D, Sala C, ... **Santini V**, et al Synthetic Data Generation by Artificial Intelligence to Accelerate Research and Precision Medicine in Hematology *JCO Clin Cancer Inform*. 2023 Jun;7:e2300021

Oliva EN, Riva M, Niscola P, **Santini V**, et al. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS). *J Clin Oncol*. 2023 Jun 9:JCO2202699. Epub ahead of print.

Platzbecker U, Della Porta MG, **Santini V, et al** . Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomized controlled trial. *Lancet*. 2023 Jun 9:S0140-6736(23)00874-7. Epub ahead of print.

Lanino L, Restuccia F, Perego A, **Santini V**, et al ; Fondazione Italiana Sindromi Mielodisplastiche (FISiM) Clinical network (<https://www.fisimematologia.it/>). Real-world efficacy and safety of luspatercept and

predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.

Am J Hematol. 2023 May 24

Zeidan AM, Giagounidis A, Sekeres MA, Xiao Z, Sanz GF, Hoef MV, Ma F, Hertle

S, **Santini V**. STIMULUS-MDS2 design and rationale: a phase III trial with the

anti-TIM-3 sibatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2.

Future Oncol. 2023 Mar;19(9):631-642. doi: 10.2217/fon-2022-1237. Epub 2023 Apr

21. PMID: 37083373.

Bewersdorf JP, Xie Z, Bejar R, Borate U, Boultonwood J, Brunner AM, Buckstein

R, Carraway HE, Churpek JE, Daver NG, Porta MGD, DeZern AE, Fenaux P, Figueroa

ME, Gore SD, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim TK,

Komrokji R, Kuchroo VK, List AF, Loghavi S, Majeti R, Odenike O, Patnaik MM,

Platzbecker U, Roboz GJ, Sallman DA, **Santini V**, Sanz G, Sekeres MA, Stahl M,

Starczynowski DT, Steensma DP, Taylor J, Abdel-Wahab O, Xu ML, Savona MR, Wei

AH, Zeidan AM. Current landscape of translational and clinical research in

myelodysplastic syndromes/neoplasms (MDS): Proceedings from the first

International Workshop on MDS (iwMDS) Of the International Consortium for MDS

(icMDS). Blood Rev. 2023 Jul; 60:101072. Epub 2023 Mar 11.

Sauta E, Robin M, Bersanelli M, Travaglino E, Meggendorfer M, Zhao LP,

Caballero Berrocal JC, Sala C, Maggioni G, Bernardi M, Di Grazia C, Vago L,

Rivoli G, Borin L, D'Amico S, Tentori CA, Ubezio M, Campagna A, Russo A, Mannina

D, Lanino L, Chiusolo P, Giaccone L, Voso MT, Riva M, Oliva EN, Zampini M, Riva

E, Nibourel O, Bicchieri M, Bolli N, Rambaldi A, Passamonti F, Savevski V,

Santoro A, Germing U, Kordasti S, **Santini V**, Diez-Campelo M, Sanz G, Sole F,

Kern W, Platzbecker U, Ades L, Fenaux P, Haferlach T, Castellani G, Della Porta

MG. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. *J Clin Oncol*. 2023 May 20;41(15):2827-2842. Epub 2023 Mar 17.

Zeidan AM, Platzbecker U, Bewersdorf JP, Stahl M, Adès L, Borate U, Bowen D, Buckstein R, Brunner A, Carraway HE, Daver N, Díez-Campelo M, de Witte T, DeZern AE, Efficace F, Garcia-Manero G, Garcia JS, Germing U, Giagounidis A, Griffiths EA, Hasserjian RP, Hellström-Lindberg E, Iastrebner M, Komrokji R, Kulasekararaj AG, Malcovati L, Miyazaki Y, Odenike O, **Santini V**, Sanz G, Scheinberg P, Stauder R, van de Loosdrecht AA, Wei AH, Sekeres MA, Fenaux P. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes. *Blood*. 2023 Apr 27;141(17):2047-2061.

Attardi E, Andolfo I, Russo R, Tiberi L, Raddi MG, Rosato BE, Marra R, Formicola D, Del Giudice F, Brogi A, Consagra A, Amato C, Sanna A, Artuso R, Iolascon A, **Santini V**. PIEZO1 mutations impact on early clinical manifestations of myelodysplastic syndromes. *Am J Hematol*. 2023 Apr;98(4):E72-E75. Epub 2023 Feb 14.

Germing U, Fenaux P, Platzbecker U, Buckstein R, **Santini V**, Díez-Campelo M, Yucel A, Tang D, Fabre S, Zhang G, Zoffoli R, Ha X, Miteva D, Hughes C, Komrokji RS, Zeidan AM, Garcia-Manero G. Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study. *Ann Hematol*. 2023 Feb;102(2):311-321. Epub 2023 Jan 13.

Itzykson R, **Santini V**, Thepot S, Ades L, Chaffaut C, Giagounidis A, Morabito M, Droin N, Lübbert M, Sapena R, Nimubona S, Goasguen J, Wattel E, Zini G, Torregrosa Diaz JM, Germing U, Pelizzari AM, Park S, Jaekel N, Metzgeroth G,

Onida F, Navarro R, Patriarca A, Stamatoullas A, Götze K, Puttrich M, Mossuto S, Solary E, Gloaguen S, Chevret S, Chermat F, Platzbecker U, Fenaux P. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network. *J Clin Oncol*. 2023 Apr 1;41(10):1888-1897. Epub 2022 Dec 1.

GenoMed4All consortium. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study. *Lancet Haematol*. 2023 Feb;10(2):e117-e128. doi: 10.1016/S2352-3026(22)00323-4. Epub 2022 Nov 24.

Shallis RM, Daver NG, Altman JK, Hasserjian RP, Kantarjian HM, Platzbecker U, **Santini V**, Wei AH, Sallman DA, Zeidan AM. TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity. *Cancer*. 2023 Jan 15;129(2):175-180. Epub 2022 Nov 17.

Stahl M, Abdel-Wahab O, Wei AH, Savona MR, Xu ML, Xie Z, Taylor J, Starczynowski D, Sanz GF, Sallman DA, **Santini V**, Roboz GJ, Patnaik MM, Padron E, Odenike O, Nazha A, Nimer SD, Majeti R, Little RF, Gore S, List AF, Kutchroo V, Komrokji RS, Kim TK, Kim N, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Greenberg PL, Figueroa M, Fenaux P, Efficace F, DeZern AE, Della Porta MG, Daver NG, Churpek JE, Carraway HE, Brunner AM, Borate U, Bennett JM, Bejar R, Boulwood J, Loghavi S, Bewersdorf JP, Platzbecker U, Steensma DP, Sekeres MA, Buckstein RJ, Zeidan AM. An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS. *Blood Adv*. 2023 Jun 27;7(12):2709-2714.

Zeidan AM, Bewersdorf JP, Buckstein R, Sekeres MA, Steensma DP, Platzbecker

U, Loghavi S, Boultonwood J, Bejar R, Bennett JM, Borate U, Brunner AM, Carraway H, Churpek JE, Daver NG, Della Porta M, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Greenberg P, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim N, Kim TK, Komrokji RS, Kutchoo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Roboz GJ, Sallman DA, Sanz G, Stahl M, Starczynowski DT, Taylor J, Xie Z, Xu M, Savona MR, Wei AH, Abdel-Wahab O, **Santini V**. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. *Leukemia*. 2022 Dec;36(12):2939-2946.

Moyo TK, Mendler JH, Itzykson R, Kishtagari A, Solary E, Seegmiller AC, Gerds AT, Ayers GD, DeZern AE, Nazha A, Valent P, van de Loosdrecht AA, Onida F, Pleyer L, Cirici BX, Tibes R, Geissler K, Komrokji RS, Zhang J, Germing U, Steensma DP, Wiseman DH, Pfeilstöcker M, Elena C, Cross NCP, Kiladjian JJ, Luebbert M, Mesa RA, Montalban-Bravo G, Sanz GF, Platzbecker U, Patnaik MM, Padron E, **Santini V**, Fenaux P, Savona MR; MDS/MPN International Working Group. The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes. *BMC Cancer*. 2022 Sep 24;22(1):1013.

Cappellini MD, **Santini V**, Braxs C, Shander A. Iron metabolism and iron deficiency anemia in women. *Fertil Steril*. 2022 Oct;118(4):607-614. Epub 2022 Sep 6.

Adema V, Ma F, Kanagal-Shamanna R, Thongon N, Montalban-Bravo G, Yang H, Peslak SA, Wang F, Acha P, Sole F, Lockyer P, Cassari M, Maciejewski JP, Visconte V, Gañán-Gómez I, Song Y, Bueso-Ramos C, Pellegrini M, Tan TM, Bejar R, Carew JS, Halene S, **Santini V**, Al-Atrash G, Clise-Dwyer K, Garcia-Manero G,

Blobel GA, Colla S. Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts. *Blood Cancer Discov.* 2022 Nov 2;3(6):554-567.

Zeidan AM, Platzbecker U, Garcia-Manero G, Sekeres MA, Fenaux P, DeZern AE, Greenberg PL, Savona MR, Jurcic JG, Verma AK, Mufti GJ, Buckstein R, **Santini V**, Shetty JK, Ito R, Zhang J, Zhang G, Ha X, Backstrom JT, Komrokji RS. Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts. *Blood.* 2022 Nov 17;140(20):2170-2174.

Adès L, Girshova L, Doronin VA, Díez-Campelo M, Valcárcel D, Kambhampati S, Viniou NA, Woszczyk D, De Paz Arias R, Symeonidis A, Anagnostopoulos A, Munhoz EC, Platzbecker U, **Santini V**, Fram RJ, Yuan Y, Friedlander S, Faller DV, Sekeres MA. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML. *Blood Adv.* 2022 Sep 13;6(17):5132-5145..

Santini V, Giagounidis A, Pelligra CG, Franco-Villalobos C, Tang D, Morison J, Beach CL, Hu A, Platzbecker U, Fenaux P. Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes. *Clin Lymphoma Myeloma Leuk.* 2022 Sep;22(9):e874-e883. Epub 2022 May 21.

Calabretto G, Attardi E, Teramo A, Trimarco V, Carraro S, Mossuto S, Barilà G, Vicenzetto C, Gasparini VR, Crugnola M, Niscola P, Poloni A, Gai V, Gaidano V, Finelli C, Bertorelle R, Candiotti C, Pizzi M, Binotto G, Facco M, Vianello F, Trentin L, Semenzato G, Zambello R, **Santini V**. Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization

in the Italian multi-center experience. *Leukemia*. 2022 Jul;36(7):1947-1950.

Epub 2022 May 21.

Mughal TI, Pemmaraju N, Bejar R, Gale RP, Bose P, Kiladjian JJ, Prchal J, Royston D, Pollyea D, Valent P, Brümmendorf TH, Skorski T, Patnaik M, **Santini V**, Fenaux P, Kucine N, Verstovsek S, Mesa R, Barbui T, Saglio G, Van Etten RA.

Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. *Hematol Oncol*. 2022 Oct;40(4):491-504. Epub 2022 Apr 15.

Buske C, Dreyling M, Alvarez-Larrán A, Apperley J, Arcaini L, Besson C, Bullinger L, Corradini P, Giovanni Della Porta M, Dimopoulos M, D'Sa S, Eich HT, Foà R, Ghia P, da Silva MG, Gribben J, Hajek R, Harrison C, Heuser M, Kieseewetter B, Kiladjian JJ, Kröger N, Moreau P, Passweg JR, Peyvandi F, Rea D, Ribera JM, Robak T, San-Miguel JF, **Santini V**, Sanz G, Sonneveld P, von Lilienfeld-Toal M, Wendtner C, Pentheroudakis G, Passamonti F. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. *ESMO Open*. 2022 Apr;7(2):100403. Epub 2022 Jan 28.

Komrokji RS, Platzbecker U, Fenaux P, Zeidan AM, Garcia-Manero G, Mufti GJ, **Santini V**, Díez-Campelo M, Finelli C, Jurcic JG, Greenberg PL, Sekeres MA, DeZern AE, Savona MR, Shetty JK, Ito R, Zhang G, Ha X, Backstrom JT, Verma A. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. *Leukemia*. 2022 May;36(5):1432-1435. Epub 2022 Feb 26.

Pilo F, Cilloni D, Della Porta MG, Forni GL, Piperno A, **Santini V**, Angelucci E. Iron-mediated tissue damage in acquired ineffective erythropoiesis disease:

It's more a matter of burden or more of exposure to toxic iron form? Leuk Res. 2022 Mar;114:106792. Epub 2022 Jan 21.

Oliva EN, Platzbecker U, Garcia-Manero G, Mufti GJ, **Santini V**, Sekeres MA, Komrokji RS, Shetty JK, Tang D, Guo S, Liao W, Zhang G, Ha X, Ito R, Lord-Bessen J, Backstrom JT, Fenaux P. Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial. J Clin Med. 2021 Dec 22;11(1):27.

Patnaik MM, Santini V. Targeting ineffective hematopoiesis in Myelodysplastic Syndromes. Am J Hematol. 2021 Nov 20. doi: 10.1002/ajh.26416. Epub ahead of print. PMID: 34800318.

Santini V, Lübbert M, Wierzbowska A, Ossenkoppele GJ. The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia. Adv Ther. 2021 Nov 16. doi: 10.1007/s12325-021-01948-8. Epub ahead of print. PMID: 34786648.

Garcia-Manero G, Mufti Obe GJ, Fenaux P, Buckstein RJ, Santini V, Díez-Campelo M, Finelli C, Ilhan O, Sekeres MA, Zeidan AM, Ito R, Zhang J, Rampersad A, Sinsimer D, Backstrom JT, Platzbecker U, Komrokji RS. Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial. Blood. 2021 Nov 10: blood.2021012589. doi: 10.1182/blood.2021012589. Epub ahead of print. PMID: 34758066.

Garcia-Manero G, Döhner H, Wei AH, La Torre I, Skikne B, Beach CL, Santini V. Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies. Clin Lymphoma Myeloma Leuk. 2021 Oct 8:S2152-2650(21)02070-X. doi:

10.1016/j.clml.2021.09.021. Epub ahead of print. PMID: 34758945.

Santini V. Advances in myelodysplastic syndrome. *Curr Opin Oncol.* 2021 Sep 1.

doi: 10.1097/CCO.0000000000000790. Epub ahead of print. PMID: 34474438.

Ward GA, McGraw KL, Abbas-Aghababazadeh F, Meyer BS, McLemore AF, Vincelette ND, Lam NB, Aldrich AL, Al Ali NH, Padron E, Pinilla-Ibarz J, Masala E, Santini V, Kosmider O, Fontenay M, Fenaux P, Johnson J, Fridley BL, List AF. Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes. *Blood Adv.* 2021 Apr 27;5(8):2216-2228. doi: 10.1182/bloodadvances.2020003475. PMID: 33890980; PMCID: PMC8095151.

Garcia-Manero G, Santini V, Almeida A, Platzbecker U, Jonasova A, Silverman LR, Falantes J, Reda G, Buccisano F, Fenaux P, Buckstein R, Diez Campelo M, Larsen S, Valcarcel D, Vyas P, Giai V, Oliva EN, Shortt J, Niederwieser D, Mittelman M, Fianchi L, La Torre I, Zhong J, Laille E, Lopes de Menezes D, Skikne B, Beach CL, Giagounidis A. Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes. *J Clin Oncol.* 2021 May 1;39(13):1426-1436. doi: 10.1200/JCO.20.02619. Epub 2021 Mar 25. PMID: 33764805; PMCID: PMC8099416.

Clavio M, Crisà E, Miglino M, Guolo F, Ceccarelli M, Salvi F, Allione B, Ferrero D, Balleari E, Finelli C, Poloni A, Selleri C, Danise P, Cilloni D, Di Tucci AA, Cametti G, Freilone R, Fanin R, Bigazzi C, Zambello R, Crugnola M, Oliva EN, Centurioni R, Alesiani F, Catarini M, Castelli A, Abbadessa A, Capalbo SF, Musto P, Angelucci E, Santini V. Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice. *Cancer.* 2021 Jun 15;127(12):2015-2024. doi: 10.1002/cncr.33472. Epub 2021 Mar 19. PMID: 33739457.

Bersanelli M, Travaglino E, Meggendorfer M, Matteuzzi T, Sala C, Mosca E, Chiereghin C, Di Nanni N, Gnocchi M, Zampini M, Rossi M, Maggioni G, Termanini A, Angelucci E, Bernardi M, Borin L, Bruno B, Bonifazi F, Santini V, Bacigalupo A, Voso MT, Oliva E, Riva M, Ubezio M, Morabito L, Campagna A, Saitta C, Savevski V, Giampieri E, Remondini D, Passamonti F, Ciceri F, Bolli N, Rambaldi A, Kern W, Kordasti S, Sole F, Palomo L, Sanz G, Santoro A, Platzbecker U, Fenaux P, Milanesi L, Haferlach T, Castellani G, Della Porta MG. Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. *J Clin Oncol*. 2021 Apr 10;39(11):1223-1233. doi: 10.1200/JCO.20.01659. Epub 2021 Feb 4. PMID: 33539200; PMCID: PMC8078359.

Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang JH, Porkka K, Selleslag D, Sandhu I, Turgut M, Giai V, Ofran Y, Kizil Çakar M, Botelho de Sousa A, Rybka J, Frairia C, Borin L, Beltrami G, Čermák J, Ossenkoppele GJ, La Torre I, Skikne B, Kumar K, Dong Q, Beach CL, Roboz GJ; QUAZAR AML-001 Trial Investigators. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. *N Engl J Med*. 2020 Dec 24;383(26):2526-2537. doi: 10.1056/NEJMoa2004444. PMID: 33369355.

Mariani M, Mattiucci D, Rossi E, Mari V, Masala E, Giuliani A, Santini V, Olivieri F, Marinelli Busilacchi E, Mancini S, Olivieri A, Poloni A. Serum Inflammation-miR Signature: A Biomarker of Myelodysplastic Syndrome? *Front Oncol*. 2020 Nov 20;10:595838. doi: 10.3389/fonc.2020.595838. PMID: 33330086; PMCID: PMC7713643.

Fenaux P, Haase D, Santini V, Sanz GF, Platzbecker U, Mey U; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and

follow-up[†]. Ann Oncol. 2021 Feb;32(2):142-156. doi:
10.1016/j.annonc.2020.11.002. Epub 2020 Nov 19. PMID: 33221366.

Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Komrokji R, Steensma D, Balleari E, Götze KS, Kotsianidis I, Guerci-Bresler A, Stamatoullas A, Sanz GF, Germing U, Fenaux P. Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents. Leuk Res. 2020 Dec;99:106472. doi:
10.1016/j.leukres.2020.106472. Epub 2020 Nov 5. PMID: 33212326.

Steensma DP, Fenaux P, Van Eygen K, Raza A, Santini V, Germing U, Font P, Diez-Campelo M, Thepot S, Vellenga E, Patnaik MM, Jang JH, Varsos H, Bussolari J, Rose E, Sherman L, Sun L, Wan Y, Dougherty S, Huang F, Feller F, Rizo A, Platzbecker U. Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study. J Clin Oncol. 2021 Jan 1;39(1):48-56. doi:
10.1200/JCO.20.01895. Epub 2020 Oct 27. PMID: 33108243.

Mossuto S, Attardi E, Alesiani F, Angelucci E, Balleari E, Bernardi M, Binotto G, Bosi C, Calvisi A, Capodanno I, Carbone A, Castelli A, Cerrano M, Ciancia R, Cilloni D, Clavio M, Clissa C, Crisà E, Crugnola M, Della Porta MG, Di Renzo N, Di Veroli A, Fattizzo R, Fava C, Fenu S, Ferrara IL, Fianchi L, Filì C, Finelli C, Giai V, Frattini F, Gaidano V, Guaragna G, Gumenyuk S, Latagliata R, Mancini S, Messa E, Molteni A, Musto P, Niscola P, Oliva E, Palumbo GA, Pelizzari A, Pilo F, Poloni A, Riva M, Rivellini F, Sarlo C, Sciumé M, Secchi R, Selleri C, Tafuri A, Santini V. SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience. Hemasphere. 2020 Sep 23;4(5):e483. doi:
10.1097/HS9.0000000000000483. PMID: 33062948; PMCID: PMC7523798.

Stojkov K, Silzle T, Stussi G, Schwappach D, Bernhard J, Bowen D, Čermák J,

Dinmohamed AG, Eeltink C, Eggmann S, Fenaux P, Germing U, Haschke M, Hellstrom-Lindberg E, Heger M, van de Loosdrecht AA, Passweg J, Pfeilstöcker M, Platzbecker U, Malcovati L, de Almeida AM, Mittelman M, Morgenthaler C, Steensma DP, Santini V, Stauder R, Symeonidis A, Schär S, Maddox C, de Witte T, Bohlius J, Bonadies N. Guideline-based indicators for adult patients with myelodysplastic syndromes. *Blood Adv.* 2020 Aug 25;4(16):4029-4044.

Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, Yoshizato T, Shiozawa Y, Saiki R, Malcovati L, Levine MF, Arango JE, Zhou Y, Solé F, Cargo CA, Haase D, Creignou M, Germing U, Zhang Y, Gundem G, Sarian A, van de Loosdrecht AA, Jädersten M, Tobiasson M, Kosmider O, Follo MY, Thol F, Pinheiro RF, Santini V, Kotsianidis I, Boulwood J, Santos FPS, Schanz J, Kasahara S, Ishikawa T, Tsurumi H, Takaori-Kondo A, Kiguchi T, Polprasert C, Bennett JM, Klimek VM, Savona MR, Belickova M, Ganster C, Palomo L, Sanz G, Ades L, Della Porta MG, Elias HK, Smith AG, Werner Y, Patel M, Viale A, Vanness K, Neuberg DS, Stevenson KE, Menghrajani K, Bolton KL, Fenaux P, Pellagatti A, Platzbecker U, Heuser M, Valent P, Chiba S, Miyazaki Y, Finelli C, Voso MT, Shih LY, Fontenay M, Jansen JH, Cervera J, Atsuta Y, Gattermann N, Ebert BL, Bejar R, Greenberg PL, Cazzola M, Hellström-Lindberg E, Ogawa S, Papaemmanuil E. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. *Nat Med.* 2020 Oct;26(10):1549-1556. doi: 10.1038/s41591-020-1008-z. Epub 2020 Aug 3. Erratum in: *Nat Med.* 2021 Mar;27(3):562. Erratum in: *Nat Med.* 2021 May;27(5):927.

Santini V, Fenaux P, Giagounidis A, Platzbecker U, List AF, Haferlach T, Zhong J, Wu C, Mavrommatis K, Beach CL, MacBeth KJ, Almeida A. Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients. *Leukemia.* 2021 Mar;35(3):897-900. doi: 10.1038/s41375-020-0961-3. Epub 2020 Jul 13.

Zeidan AM, Boddu PC, Patnaik MM, Bewersdorf JP, Stahl M, Rampal RK, Shallis R, Steensma DP, Savona MR, Sekeres MA, Roboz GJ, DeAngelo DJ, Schuh AC, Padron E, Zeidner JF, Walter RB, Onida F, Fathi A, DeZern A, Hobbs G, Stein EM, Vyas P, Wei AH, Bowen DT, Montesinos P, Griffiths EA, Verma AK, Keyzner A, Bar-Natan M, Navada SC, Kremyanskaya M, Goldberg AD, Al-Kali A, Heaney ML, Nazha A, Salman H, Luger S, Pratz KW, Konig H, Komrokji R, Deininger M, Cirici BX, Bhatt VR, Silverman LR, Erba HP, Fenau P, Platzbecker U, Santini V, Wang ES, Tallman MS, Stone RM, Mascarenhas J. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. *Lancet Haematol*. 2020 Aug;7(8):e601-e612. doi: 10.1016/S2352-3026(20)30205-2. Epub 2020 Jun 18.

Cilloni D, Ravera S, Calabrese C, Gaidano V, Niscola P, Balleari E, Gallo D, Petiti J, Signorino E, Rosso V, Panuzzo C, Sabatini F, Andreani G, Dragani M, Finelli C, Poloni A, Crugnola M, Voso MT, Fenu S, Pelizzari A, Santini V, Saglio G, Podestà M, Frassoni F. Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study. *Sci Rep*. 2020 Jun 8;10(1):9156. doi: 10.1038/s41598-020-66162-y.

Angelucci E, Li J, Greenberg P, Wu D, Hou M, Montano Figueroa EH, Rodriguez MG, Dong X, Ghosh J, Izquierdo M, Garcia-Manero G; TELESTO Study Investigators. Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial. *Ann Intern Med*. 2020 Apr 21;172(8):513-522. doi: 10.7326/M19-0916. Epub 2020 Mar 24.

Santini V. Enasidenib: a magic bullet for myelodysplastic syndromes? *Lancet Haematol*. 2020 Apr;7(4):e275-e276. doi: 10.1016/S2352-3026(20)30039-9. Epub 2020 Mar 5..

Crisà E, Kulasekararaj AG, Adema V, Such E, Schanz J, Haase D, Shirneshan K,

Best S, Mian SA, Kizilors A, Cervera J, Lea N, Ferrero D, Germing U, Hildebrandt B, Martínez ABV, Santini V, Sanz GF, Solé F, Mufti GJ. Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7. *Leukemia*. 2020 Sep;34(9):2441-2450. doi: 10.1038/s41375-020-0728-x. Epub 2020 Feb 17.

Santini V, Almeida A, Giagounidis A, Skikne B, Beach CL, Weaver J, Tu N, Fenaux P. Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels. *Leuk Lymphoma*. 2020 Jun;61(6):1475-1483. doi: 10.1080/10428194.2020.1719088. Epub 2020 Feb 17.

Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. *N Engl J Med*. 2020 Jan 9;382(2):140-151.

Itzykson R, Fenaux P, Bowen D, Cross NCP, Cortes J, De Witte T, Germing U, Onida F, Padron E, Platzbecker U, Santini V, Sanz GF, Solary E, Van de Loosdrecht A, Malcovati L. Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet. *Hemasphere*. 2018 Nov 29;2(6):e150.

Balleari E, Filiberti RA, Salvetti C, Allione B, Angelucci E, Bruzzone M, Calzamiglia T, Cavaliere M, Cavalleri M, Cilloni D, Clavio M, Crisà E, Da Col A, Danise P, Pilo F, Ferrero D, Finelli C, Gioia D, Lemoli RM, Masiera E, Messa E,

Migliano M, Musto P, Natalie Oliva E, Poloni A, Salvi F, Sanna A, Scudeletti M, Tassara R, Santini V. Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis. *Cancer Med*. 2019 Dec;8(18):7567-7576.

Santini V, Valcárcel D, Platzbecker U, Komrokji RS, Cleverly AL, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Gueorguieva I, Girvan AC, da Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Sridharan A, Will B, Verma A. Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes. *Clin Cancer Res*. 2019 Dec 1;25(23):6976-6985. Epub 2019 Sep 3.

Bondu S, Alary AS, Lefèvre C, Houy A, Jung G, Lefebvre T, Rombaut D, Boussaid I, Bousta A, Guillonneau F, Perrier P, Alsafadi S, Wassef M, Margueron R, Rousseau A, Droin N, Cagnard N, Kaltenbach S, Winter S, Kubasch AS, Bouscary D, Santini V, Toma A, Hunault M, Stamatoullas A, Gyan E, Cluzeau T, Platzbecker U, Adès L, Puy H, Stern MH, Karim Z, Mayeux P, Nemeth E, Park S, Ganz T, Kautz L, Kosmider O, Fontenay M. A variant erythroferrone disrupts iron homeostasis in *SF3B1*-mutated myelodysplastic syndrome. *Sci Transl Med*. 2019 Jul 10;11(500):eaav5467.

Santini V, Ossenkoppele GJ. Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use. *Crit Rev Oncol Hematol*. 2019 Aug;140:1-7. doi: 10.1016/j.critrevonc.2019.05.013. Epub 2019 May 25.

Garcia-Manero G, Almeida A, Fenaux P, Gattermann N, Giagounidis A, Goldberg SL, Ozawa K, Weaver J, Santini V. Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial. *Clin Lymphoma Myeloma Leuk*. 2019 Apr;19(4):213-219.e4. doi: 10.1016/j.clml.2018.12.012. Epub 2018 Dec 21.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultonwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. *Leukemia*. 2019 Jul;33(7):1747-1758. doi: 10.1038/s41375-018-0351-2. Epub 2019 Jan 11.

Santini V. How I treat MDS after hypomethylating agent failure. *Blood*. 2019 Feb 7;133(6):521-529. doi: 10.1182/blood-2018-03-785915. Epub 2018 Dec 13.

Girmenia C, Candoni A, Delia M, Latagliata R, Molteni A, Oliva EN, Palumbo GA, Poloni A, Salutari P, Santini V, Voso MT, Musto P. Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations. *Blood Rev*. 2019 Mar;34:16-25. Epub 2018 Oct 28.

Platzbecker U, Fenaux P, Adès L, Giagounidis A, Santini V, van de Loosdrecht AA, Bowen D, de Witte T, Garcia-Manero G, Hellström-Lindberg E, Germing U, Stauder R, Malcovati L, Sekeres MA, Steensma DP, Gloaguen S. Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. *Blood*. 2019 Mar 7;133(10):1020-1030. Epub 2018 Nov 7.

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers

D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. *Ann Oncol*. 2018 Oct 1;29(Suppl 4):iv271.

Erratum for: *Ann Oncol*. 2018 Oct 1;29(Suppl 4):iv96-iv110.

Döhner H, Dolnik A, Tang L, Seymour JF, Minden MD, Stone RM, Del Castillo TB, Al-Ali HK, Santini V, Vyas P, Beach CL, MacBeth KJ, Skikne BS, Songer S, Tu N, Bullinger L, Dombret H. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. *Leukemia*. 2018 Dec;32(12):2546-2557.

Epub 2018 Oct 1.

Miyazaki Y, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Santini V, Lübbert M, Maciejewski J, Machherndl-Spandl S, Magalhaes SMM, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL. Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. *Leuk Res*. 2018 Oct;73:51-57. doi: 10.1016/j.leukres.2018.08.022. Epub 2018 Sep 6. PMID: 30219650.

Messa E, Gioia D, Masiera E, Castiglione A, Ceccarelli M, Salvi F, Danise P, Sanna A, Allione B, Balleari E, Poloni A, Cametti G, Ferrero D, Tassara R, Finelli C, Bonferroni M, Musto P, Saglio G, Levis A, Santini V. Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study. *Haematologica*. 2019 Jan;104(1):e4-e8. doi: 10.3324/haematol.2017.183590. Epub 2018 Aug 3. PMID: 30076178; PMCID: PMC6312022.

Basiorka AA, McGraw KL, Abbas-Aghababazadeh F, McLemore AF, Vincelette ND, Ward GA, Eksioglu EA, Sallman DA, Ali NA, Padron E, Pinilla-Ibarz J, Komrokji R, Masala E, Santini V, Kosmider O, Fontenay M, Fenaux P, Sokol L, Wei S, Fridley B, List AF. Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study. *Lancet Haematol.* 2018 Sep;5(9):e393-e402. doi: 10.1016/S2352-3026(18)30109-1. Epub 2018 Jul 30. PMID: 30072146; PMCID: PMC6505461.

Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie EK, Verma V, Nazha A, Maciejewski JP, Podoltsev NA, Prebet T, Santini V, Gore SD, Komrokji RS, Zeidan AM. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. *Blood Adv.* 2018 Jul 24;2(14):1765-1772. doi: 10.1182/bloodadvances.2018019414. PMID: 30037803; PMCID: PMC6058241.

Niyongere S, Lucas N, Zhou JM, Sansil S, Pomicter AD, Balasis ME, Robinson J, Kroeger J, Zhang Q, Zhao YL, Ball M, Komrokji R, List A, Deininger MW, Fridley BL, Santini V, Solary E, Padron E. Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. *Leukemia.* 2019 Jan;33(1):205-216. doi: 10.1038/s41375-018-0203-0. Epub 2018 Jul 19. PMID: 30026572; PMCID: PMC7787307.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore SD, Zeidan AM. Performance of the Medical Research Council (MRC) and the Leukemia Research

Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. *Leuk Lymphoma*. 2019 Jan;60(1):246-249. doi: 10.1080/10428194.2018.1468893. Epub 2018 Jul 2. PMID: 29963936.

Santini V. Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes. *Clin Lymphoma Myeloma Leuk*. 2018 Aug;18(8):495-500. doi: 10.1016/j.clml.2018.05.013. Epub 2018 May 23. PMID: 29907542.

Fenaux P, Santini V, Spiriti MAA, Giagounidis A, Schlag R, Radinoff A, Gercheva-Kyuchukova L, Anagnostopoulos A, Oliva EN, Symeonidis A, Berger MH, Götze KS, Potamianou A, Haralampiev H, Wapenaar R, Milionis I, Platzbecker U. A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin- α in anemic patients with low-risk MDS. *Leukemia*. 2018 Dec;32(12):2648-2658. doi: 10.1038/s41375-018-0118-9. Epub 2018 Mar 30. PMID: 29895954; PMCID: PMC6286328.

Duchmann M, Yalniz FF, Sanna A, Sallman D, Coombs CC, Renneville A, Kosmider O, Braun T, Platzbecker U, Willems L, Adès L, Fontenay M, Rampal R, Padron E, Droin N, Preudhomme C, Santini V, Patnaik MM, Fenaux P, Solary E, Itzykson R. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. *EBioMedicine*. 2018 May;31:174-181. doi: 10.1016/j.ebiom.2018.04.018. Epub 2018 Apr 25. PMID: 29728305; PMCID: PMC6013781.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, Gore SD, Zeidan AM.

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. *Blood Adv.* 2018 Apr 24;2(8):923-932. doi: 10.1182/bloodadvances.2018016121. PMID: 29685952; PMCID: PMC5916007.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Majhail N, Barnard J, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Kobbe G, Bergua J, Serrano J, Gore SD, Zeidan AM. Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. *Biol Blood Marrow Transplant.* 2018 Aug;24(8):1754-1758. doi: 10.1016/j.bbmt.2018.03.025. Epub 2018 Apr 9. PMID: 29649620.

Arcioni F, Roncadori A, Di Battista V, Tura S, Covezzoli A, Cundari S, Mecucci C; MORE Study Centres. Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency. *Eur J Haematol.* 2018 Jul;101(1):78-85. doi: 10.1111/ejh.13067. Epub 2018 May 22. PMID: 29569278.

Masala E, Valencia-Martinez A, Pillozzi S, Rondelli T, Brogi A, Sanna A, Gozzini A, Arcangeli A, Sbarba PD, Santini V. Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow cell cultures. *Oncotarget.* 2018 Jan 24;9(12):10561-10571. doi: 10.18632/oncotarget.24302. PMID: 29535827; PMCID: PMC5828219.

Santini V, Almeida A, Giagounidis A, Platzbecker U, Buckstein R, Beach CL, Guo S, Altincatal A, Wu C, Fenaux P. The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic

Syndromes: Results From the MDS-005 Study. *Clin Lymphoma Myeloma Leuk*. 2018 Feb;18(2):136-144.e7. doi: 10.1016/j.clml.2017.12.004. Epub 2017 Dec 30. PMID: 29429612.

Santini V. Of blood and bone: the sotatercept adventure. *Lancet Haematol*. 2018 Feb;5(2):e54-e55. doi: 10.1016/S2352-3026(18)30003-6. Epub 2018 Jan 10. PMID: 29331634.

Almeida A, Fenaux P, Garcia-Manero G, Goldberg SL, Gröpper S, Jonasova A, Vey N, Castaneda C, Zhong J, Beach CL, Santini V. Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial. *Leuk Lymphoma*. 2018 Sep;59(9):2135-2143. doi: 10.1080/10428194.2017.1421758. Epub 2018 Jan 11. PMID: 29322849.

Nazha A, Sekeres MA, Komrokji R, Steensma DP, Kantarjian H, Roboz G, Fenaux P, Prebet T, Azarnia N, Zbyszewski PS, Fruchtman SM, Santini V, Silverman LR, Platzbecker U, Garcia-Manero G. Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care. *Blood Cancer J*. 2017 Dec 14;7(12):644. doi: 10.1038/s41408-017-0018-7. PMID: 29238044; PMCID: PMC5802598.

Sébert M, Komrokji RS, Sekeres MA, Prebet T, Cluzeau T, Santini V, Gyan E, Sanna A, Ali NH, Hobson S, Eclache V, List A, Fenaux P, Adès L. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine. *Leuk Res*. 2017 Dec;63:72-77. doi: 10.1016/j.leukres.2017.10.013. Epub 2017 Oct 27. PMID: 29112938.

Cluzeau T, McGraw KL, Irvine B, Masala E, Ades L, Basiorka AA, Maciejewski

J, Auberger P, Wei S, Fenaux P, Santini V, List A. Pro-inflammatory proteins S100A9 and tumor necrosis factor- α suppress erythropoietin elaboration in myelodysplastic syndromes. *Haematologica*. 2017 Dec;102(12):2015-2020. doi: 10.3324/haematol.2016.158857. Epub 2017 Oct 5. PMID: 28983059; PMCID: PMC5709100.

Zaninetti C, Santini V, Tiniakou M, Barozzi S, Savoia A, Pecci A. Inherited thrombocytopenia caused by ANKRD26 mutations misdiagnosed and treated as myelodysplastic syndrome: report on two cases. *J Thromb Haemost*. 2017 Dec;15(12):2388-2392. doi: 10.1111/jth.13855. Epub 2017 Oct 28. PMID: 28976612.

Santini V. Defeating anaemia in myelodysplastic syndromes: another step forward. *Lancet Oncol*. 2017 Oct;18(10):1290-1292. doi: 10.1016/S1470-2045(17)30671-X. Epub 2017 Sep 1. PMID: 28870613.

Santini V. First-line Therapeutic Strategies for Myelodysplastic Syndromes. *Clin Lymphoma Myeloma Leuk*. 2017 Jul;17S:S31-S36. doi: 10.1016/j.clml.2017.02.013. PMID: 28760300.

Buckstein R, Balleari E, Wells R, Santini V, Sanna A, Salvetti C, Crisà E, Allione B, Danise P, Finelli C, Clavio M, Poloni A, Salvi F, Cilloni D, Oliva EN, Musto P, Houston B, Zhu N, Geddes M, Leitch H, Leber B, Sabloff M, Nevill TJ, Yee KW, Storrington JM, Francis J, Maurillo L, Latagliata R, Spiriti MAA, Andriani A, Piccioni AL, Fianchi L, Fenu S, Gumenyuk S, Buccisano F. ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems. *Am J Hematol*. 2017 Oct;92(10):1037-1046. doi: 10.1002/ajh.24842. Epub 2017 Jul 29. PMID: 28675513.

Santini V, Allione B, Zini G, Gioia D, Lunghi M, Poloni A, Cilloni D, Sanna

A, Masiera E, Ceccarelli M, Abdel-Wahab O, Terenzi A, Angelucci E, Finelli C, Onida F, Pelizzari A, Ferrero D, Saglio G, Figueroa M, Levis A. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. *Leukemia*. 2018 Feb;32(2):413-418. doi: 10.1038/leu.2017.186. Epub 2017 Jun 13. PMID: 28607470; PMCID: PMC5808077.

Valencia-Martinez A, Sanna A, Masala E, Contini E, Brogi A, Gozzini A, Santini V. Mutated ASXL1 and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasia. *Haematologica*. 2017 Sep;102(9):e332-e335. doi: 10.3324/haematol.2017.166124. Epub 2017 May 18. PMID: 28522578; PMCID: PMC5685232.

Musto P, Maurillo L, Simeon V, Poloni A, Finelli C, Balleari E, Ricco A, Rivellini F, Cortelezzi A, Tarantini G, Villani O, Mansueto G, Milella MR, Scapicchio D, Marziano G, Breccia M, Niscola P, Sanna A, Clissa C, Voso MT, Fenu S, Venditti A, Santini V, Angelucci E, Levis A. Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. *Br J Haematol*. 2017 Jun;177(5):741-750. doi: 10.1111/bjh.14621. Epub 2017 Apr 17. PMID: 28419408.

Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. *J Clin Oncol*. 2017 May 10;35(14):1591-1597. doi: 10.1200/JCO.2016.71.3271. Epub 2017 Mar 28. PMID:

28350519.

Della Porta MG, Jackson CH, Alessandrino EP, Rossi M, Bacigalupo A, van Lint MT, Bernardi M, Allione B, Bosi A, Guidi S, Santini V, Malcovati L, Ubezio M, Milanesi C, Todisco E, Voso MT, Musto P, Onida F, Iori AP, Cerretti R, Grillo G, Molteni A, Pioltelli P, Borin L, Angelucci E, Oldani E, Sica S, Pascutto C, Ferretti V, Santoro A, Bonifazi F, Cazzola M, Rambaldi A. Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. *Leukemia*. 2017 Nov;31(11):2449-2457. doi: 10.1038/leu.2017.88. Epub 2017 Mar 21. PMID: 28321120; PMCID: PMC6086331.

Varaldo R, Raiola AM, Di Grazia C, Aquino S, Beltrami G, Bregante S, Cruciani F, Dominietto A, Ghiso A, Giannoni L, Gualandi F, Ibatici A, Lamparelli T, Marani C, Van Lint MT, Santini V, Bacigalupo A, Angelucci E. Haploidentical bone marrow transplantation in patients with advanced myelodysplastic syndrome. *Am J Hematol*. 2017 Jun;92(6):E117-E119. doi: 10.1002/ajh.24725. Epub 2017 Apr 29. PMID: 28316085.

Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, Salvi F, Sanpaolo G, Balleari E, Germing U, Fenaux P, Stamatoullas A, Palumbo GA, Salutari P, Impera S, Avanzini P, Cortelezzi A, Liberati AM, Carluccio P, Buccisano F, Voso MT, Mancini S, Kulasekararaj A, Morabito F, Bocchia M, Cufari P, Spiriti MA, Santacaterina I, D'Errigo MG, Bova I, Zini G, Latagliata R. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. *Lancet Haematol*. 2017 Mar;4(3):e127-e136. doi: 10.1016/S2352-3026(17)30012-1. Epub 2017 Feb 3. PMID: 28162984.

Santini V. Treatment of low-risk myelodysplastic syndromes. *Hematology Am*

Soc Hematol Educ Program. 2016 Dec 2;2016(1):462-469. doi: 10.1182/asheducation-2016.1.462. PMID: 27913517; PMCID: PMC6142510.

Almeida A, Fenaux P, List AF, Raza A, Platzbecker U, Santini V. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). *Leuk Res*. 2017 Jan;52:50-57. doi: 10.1016/j.leukres.2016.11.008. Epub 2016 Nov 13. PMID: 27883945.

Negoro E, Radivoyevitch T, Polprasert C, Adema V, Hosono N, Makishima H, Przychodzen B, Hirsch C, Clemente MJ, Nazha A, Santini V, McGraw KL, List AF, Sole F, Sekeres MA, Maciejewski JP. Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide. *Leukemia*. 2016 Dec;30(12):2405-2409. doi: 10.1038/leu.2016.228. Epub 2016 Aug 18. PMID: 27560106; PMCID: PMC5143200.

Santini V, Almeida A, Giagounidis A, Gröpper S, Jonasova A, Vey N, Mufti GJ, Buckstein R, Mittelman M, Platzbecker U, Shpilberg O, Ram R, Del Cañizo C, Gattermann N, Ozawa K, Risueño A, MacBeth KJ, Zhong J, Séguy F, Hoenekopp A, Beach CL, Fenaux P. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. *J Clin Oncol*. 2016 Sep 1;34(25):2988-96. doi: 10.1200/JCO.2015.66.0118. Epub 2016 Jun 27. PMID: 27354480.

Garcia-Manero G, Almeida A, Giagounidis A, Platzbecker U, Garcia R, Voso MT, Larsen SR, Valcarcel D, Silverman LR, Skikne B, Santini V. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and

thrombocytopenia. *BMC Hematol.* 2016 May 3;16:12. doi: 10.1186/s12878-016-0049-5. PMID: 27148452; PMCID: PMC4855808.

Kosmider O, Passet M, Santini V, Platzbecker U, Andrieu V, Zini G, Beyne-Rauzy O, Guerci A, Masala E, Balleari E, Bulycheva E, Dreyfus F, Fenaux P, Fontenay M, Park S; GFM, FISM AND D-MDS. Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes? *Haematologica.* 2016 Jul;101(7):e280-3. doi: 10.3324/haematol.2016.142695. Epub 2016 Apr 7. PMID: 27056923; PMCID: PMC5004472.

Gyan E, Andrieu V, Sanna A, Caille A, Schemenau J, Sudaka I, Siguret V, Malet M, Park S, Bordessoule D, Mairesse J, Gelsi-Boyer V, Cheze S, Beyne-Rauzy O, Sébert M, Sapena R, Zerazhi H, Legros L, Guerci-Bresler A, Amé SN, Germing U, Santini V, Salvi F, Gioia D, Lunghi M, Dreyfus F, Fenaux P; Groupe Francophone des Myélodysplasies, Fondazione Italiana per le Sindromi Mielodisplastiche (FISMonlus), and Düsseldorf MDS Registry. Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis. *Br J Haematol.* 2016 Dec;175(5):975-979. doi: 10.1111/bjh.13902. Epub 2016 Jan 15. PMID: 26773632.

Guryanova OA, Lieu YK, Garrett-Bakelman FE, Spitzer B, Glass JL, Shank K, Martinez AB, Rivera SA, Durham BH, Rapaport F, Keller MD, Pandey S, Bastian L, Tovbin D, Weinstein AR, Teruya-Feldstein J, Abdel-Wahab O, Santini V, Mason CE, Melnick AM, Mukherjee S, Levine RL. Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells. *Leukemia.* 2016 May;30(5):1133-42. doi: 10.1038/leu.2015.358. Epub 2015 Dec 29. PMID: 26710888; PMCID: PMC4856586.

Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. *Lancet Haematol*. 2015 Oct;2(10):e417-26. doi: 10.1016/S2352-3026(15)00149-0. Epub 2015 Oct 1. PMID: 26686043.

Santini V. Anemia as the Main Manifestation of Myelodysplastic Syndromes. *Semin Hematol*. 2015 Oct;52(4):348-56. doi: 10.1053/j.seminhematol.2015.06.002. Epub 2015 Jun 30. PMID: 26404446.

Russo D, Malagola M, Skert C, Cancelli V, Turri D, Pregno P, Bergamaschi M, Fogli M, Testoni N, De Vivo A, Castagnetti F, Pungolino E, Stagno F, Breccia M, Martino B, Intermesoli T, Cambrin GR, Nicolini G, Abruzzese E, Tiribelli M, Bigazzi C, Usala E, Russo S, Russo-Rossi A, Lunghi M, Bocchia M, D'Emilio A, Santini V, Girasoli M, Lorenzo RD, Bernardi S, Palma AD, Cesana BM, Soverini S, Martinelli G, Rosti G, Baccarani M. Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. *Blood Cancer J*. 2015 Sep 18;5(9):e347. doi: 10.1038/bcj.2015.75. PMID: 26383820; PMCID: PMC4648524.

Nolte F, Angelucci E, Breccia M, Gattermann N, Santini V, Vey N, Hofmann WK. Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome - Emphasis on optimized dosing schedules and new formulations. *Leuk Res*. 2015 Oct;39(10):1028-33. doi: 10.1016/j.leukres.2015.06.008. Epub 2015 Jun 20. PMID: 26293555.

Meldi K, Qin T, Buchi F, Droin N, Sotzen J, Micol JB, Selimoglu-Buet D, Masala E, Allione B, Gioia D, Poloni A, Lunghi M, Solary E, Abdel-Wahab O, Santini V, Figueroa ME. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. *J Clin Invest*. 2015 May;125(5):1857-72. doi: 10.1172/JCI78752. Epub 2015 Mar 30. PMID: 25822018; PMCID: PMC4611703.

Santini V. Life after hypomethylating agents in myelodysplastic syndrome: new strategies. *Curr Opin Hematol*. 2015 Mar;22(2):155-62. doi: 10.1097/MOH.0000000000000117. PMID: 25603477.

Santini V, Fenaux P. Treatment of myelodysplastic syndrome with thrombomimetic drugs. *Semin Hematol*. 2015 Jan;52(1):38-45. doi: 10.1053/j.seminhematol.2014.10.005. Epub 2014 Oct 31. PMID: 25578418.

Santini V. On raising the "dust of blood": from unrevealing thrombopoiesis to treatment of thrombocytopenias with thrombomimetic drugs. *Semin Hematol*. 2015 Jan;52(1):1-3. doi: 10.1053/j.seminhematol.2014.10.008. Epub 2014 Oct 31. PMID: 25578412.

Santini V, Prebet T, Fenaux P, Gattermann N, Nilsson L, Pfeilstöcker M, Vyas P, List AF. Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. *Leuk Res*. 2014 Dec;38(12):1381-91. doi: 10.1016/j.leukres.2014.09.008. Epub 2014 Sep 22. PMID: 25444075.

Castagnetti F, Gugliotta G, Baccharani M, Breccia M, Specchia G, Levato L, Abruzzese E, Rossi G, Iurlo A, Martino B, Pugno P, Stagno F, Cuneo A, Bonifacio M, Gobbi M, Russo D, Gozzini A, Tiribelli M, de Vivo A, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G; GIMEMA CML Working Party. Differences

among young adults, adults and elderly chronic myeloid leukemia patients. *Ann Oncol.* 2015 Jan;26(1):185-192. doi: 10.1093/annonc/mdu490. Epub 2014 Oct 30. PMID: 25361995.

Efficace F, Santini V, La Nasa G, Cottone F, Finelli C, Borin L, Quaresmini G, Di Tucci AA, Volpe A, Cilloni D, Quarta G, Sanpaolo G, Rivellini F, Salvi F, Molteni A, Voso MT, Alimena G, Fenu S, Mandelli F, Angelucci E. Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy. *BMJ Support Palliat Care.* 2016 Mar;6(1):80-8. doi: 10.1136/bmjspcare-2014-000726. Epub 2014 Sep 9. PMID: 25204541.

Fenaux P, Haase D, Sanz GF, Santini V, Buske C; ESMO Guidelines Working Group. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2014 Sep;25 Suppl 3:iii57-69. doi: 10.1093/annonc/mdu180. Epub 2014 Jul 25. PMID: 25185242.

Voso MT, Santini V, Fabiani E, Fianchi L, Criscuolo M, Falconi G, Guidi F, Hohaus S, Leone G. Why methylation is not a marker predictive of response to hypomethylating agents. *Haematologica.* 2014 Apr;99(4):613-9. doi: 10.3324/haematol.2013.099549. PMID: 24688109; PMCID: PMC3971070.

Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial). *Eur J Haematol.* 2014 Jun;92(6):527-36. doi: 10.1111/ejh.12300. Epub 2014 Apr 10. PMID: 24580147.

Temraz S, Santini V, Musallam K, Taher A. Iron overload and chelation therapy in myelodysplastic syndromes. *Crit Rev Oncol Hematol*. 2014 Jul;91(1):64-73. doi: 10.1016/j.critrevonc.2014.01.006. Epub 2014 Jan 24. PMID: 24529413.

Adès L, Santini V. Hypomethylating agents and chemotherapy in MDS. *Best Pract Res Clin Haematol*. 2013 Dec;26(4):411-9. doi: 10.1016/j.beha.2013.09.010. Epub 2013 Oct 7. PMID: 24507817.

Alhan C, Westers TM, van der Helm LH, Eeltink C, Huls G, Witte BI, Buchi F, Santini V, Ossenkoppele GJ, van de Loosdrecht AA. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes. *Cytometry B Clin Cytom*. 2014 May;86(3):207-15. doi: 10.1002/cyto.b.21160. Epub 2014 Jan 28. PMID: 24474614.

Seymour JF, Bennett JM, List AF, Mufti GJ, Gore SD, Fenaux P, Santini V, Hetzer J, Songer S, Skikne BS, Beach CL. Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes. *Br J Haematol*. 2014 Apr;165(1):49-56. doi: 10.1111/bjh.12723. Epub 2014 Jan 28. PMID: 24467613.

Fenaux P, Seymour JF, Santini V, Silverman L, Gore S, List A, Sanz G, Mufti GJ, Estey E, Swern AS, Beach CL, Hellstrom-Lindberg E. Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model. *Leuk Res*. 2014 Feb;38(2):258-62. doi: 10.1016/j.leukres.2013.10.014. Epub 2013 Oct 27. PMID: 24360612.

Buchi F, Masala E, Rossi A, Valencia A, Spinelli E, Sanna A, Gozzini A, Santini V. Redistribution of H3K27me3 and acetylated histone H4 upon exposure to

azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3. *Epigenetics*. 2014 Mar;9(3):387-95. doi: 10.4161/epi.27322. Epub 2013 Dec 2. PMID: 24300456; PMCID: PMC4053457.

Valencia A, Masala E, Rossi A, Martino A, Sanna A, Buchi F, Canzian F, Cilloni D, Gaidano V, Voso MT, Kosmider O, Fontenay M, Gozzini A, Bosi A, Santini V. Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. *Leukemia*. 2014 Mar;28(3):621-8. doi: 10.1038/leu.2013.330. Epub 2013 Nov 6. PMID: 24192812; PMCID: PMC3948159.

Santini V, Schemenau J, Levis A, Balleari E, Sapena R, Adès L, Guerci A, Beyne-Rauzy O, Gourin MP, Cheze S, Stamatoullas A, Sanna A, Gioia D, Cametti G, Ferrero D, Raffoux E, Rose C, Poloni A, Prebet T, Legros L, Natarajan-Amé S, Fenaux P, Germing U, Dreyfus F, Park S. Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? *Blood*. 2013 Sep 26;122(13):2286-8. doi: 10.1182/blood-2013-07-512442. PMID: 24072851.

Onida F, Barosi G, Leone G, Malcovati L, Morra E, Santini V, Specchia G, Tura S. Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups. *Haematologica*. 2013 Sep;98(9):1344-52. doi: 10.3324/haematol.2013.084020. PMID: 24006407; PMCID: PMC3762089.

Santini V, Melnick A, Maciejewski JP, Duprez E, Nervi C, Cocco L, Ford KG, Mufti G. Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. *Crit Rev Oncol Hematol*. 2013 Nov;88(2):231-45. doi: 10.1016/j.critrevonc.2013.06.004. Epub 2013 Jul 7. PMID: 23838480.

Gore SD, Fenaux P, Santini V, Bennett JM, Silverman LR, Seymour JF, Hellström-Lindberg E, Swern AS, Beach CL, List AF. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. *Haematologica*. 2013 Jul;98(7):1067-72. doi: 10.3324/haematol.2012.074831. Epub 2013 Apr 12. PMID: 23585522; PMCID: PMC3696610.

Sardnal V, Rouquette A, Kaltenbach S, Bally C, Chesnais V, Leschi C, Ades L, Santini V, Park S, Toma A, Fenaux P, Dreyfus F, Fontenay M, Kosmider O. A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q). *Leukemia*. 2013 Jul;27(7):1610-3. doi: 10.1038/leu.2013.59. Epub 2013 Feb 26. PMID: 23434730.

Barbetti V, Gozzini A, Cheloni G, Marzi I, Fabiani E, Santini V, Dello Sbarba P, Rovida E. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells. *Epigenetics*. 2013 Feb;8(2):210-9. doi: 10.4161/epi.23538. Epub 2013 Jan 15. Erratum in: *Epigenetics*. 2013 Dec;8(12):1384. PMID: 23321683; PMCID: PMC3592907.

Mannelli F, Bencini S, Peruzzi B, Cutini I, Sanna A, Benelli M, Magi A, Gianfaldoni G, Rotunno G, Carrai V, Gelli AM, Valle V, Santini V, Notaro R, Luzzatto L, Bosi A. A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria. *Cytometry B Clin Cytom*. 2013 Mar;84(2):71-81. doi: 10.1002/cyto.b.21064. Epub 2012 Dec 26. PMID: 23281097.

Swords R, Santini V. In elderly patients with AML, which patients should be considered fit or unfit for standard induction therapy? *Hematology Am Soc Hematol Educ Program*. 2012;2012:74-5. doi: 10.1182/asheducation-2012.1.74. PMID:

23233563.

Santini V. Novel therapeutic strategies: hypomethylating agents and beyond. *Hematology Am Soc Hematol Educ Program*. 2012;2012:65-73. doi: 10.1182/asheducation-2012.1.65. Erratum in: *Hematology Am Soc Hematol Educ Program*. 2013;2013:692. PMID: 23233562.

Breccia M, Fianchi L, Lunghi M, Gaidano G, Levis A, Finelli C, Santini V, Musto P, Mansueto G, Oliva EN, Leoni P, Spiriti MA, Hohaus S, Leone G, Alimena G, Voso MT. Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine. *Leuk Lymphoma*. 2013 Aug;54(8):1786-7. doi: 10.3109/10428194.2012.749406. Epub 2012 Dec 10. PMID: 23151268.

Santini V. Treatment of low-risk myelodysplastic syndrome: hematopoietic growth factors erythropoietins and thrombopoietins. *Semin Hematol*. 2012 Oct;49(4):295-303. doi: 10.1053/j.seminhematol.2012.09.003. PMID: 23079059.

Fianchi L, Criscuolo M, Breccia M, Maurillo L, Salvi F, Musto P, Mansueto G, Gaidano G, Finelli C, Aloe-Spiriti A, Santini V, Greco M, Hohaus S, Leone G, Voso MT. High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. *Leuk Lymphoma*. 2013 Mar;54(3):658-61. doi: 10.3109/10428194.2012.719617. Epub 2012 Aug 30. PMID: 22873829.

Fianchi L, Criscuolo M, Lunghi M, Gaidano G, Breccia M, Levis A, Finelli C, Santini V, Musto P, Oliva EN, Leoni P, Aloe Spiriti A, D'Alò F, Hohaus S, Pagano L, Leone G, Voso MT. Outcome of therapy-related myeloid neoplasms treated with azacitidine. *J Hematol Oncol*. 2012 Aug 1;5:44. doi: 10.1186/1756-8722-5-44.

PMID: 22853048; PMCID: PMC3419605.

Oliva EN, Finelli C, Santini V, Poloni A, Liso V, Cilloni D, Impera S, Terenzi A, Levis A, Cortelezzi A, Ghio R, Musto P, Semenzato G, Clissa C, Lunghi T, Trappolini S, Gaidano V, Salvi F, Reda G, Villani O, Binotto G, Cufari P, Cavalieri E, Spiriti MA. Quality of life and physicians' perception in myelodysplastic syndromes. *Am J Blood Res.* 2012;2(2):136-47. Epub 2012 May 25.

PMID: 22762033; PMCID: PMC3384400.

Masala E, Valencia A, Buchi F, Nosi D, Spinelli E, Gozzini A, Sassolini F, Sanna A, Zecchi S, Bosi A, Santini V. Hypermethylation of Wnt antagonist gene promoters and activation of Wnt pathway in myelodysplastic marrow cells. *Leuk Res.* 2012 Oct;36(10):1290-5. doi: 10.1016/j.leukres.2012.05.023. Epub 2012 Jun 27. PMID: 22742816.

Spinelli E, Caporale R, Buchi F, Masala E, Gozzini A, Sanna A, Sassolini F, Valencia A, Bosi A, Santini V. Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients. *Clin Cancer Res.* 2012 Jun 1;18(11):3079-89. doi: 10.1158/1078-0432.CCR-11-0686. Epub 2012 Apr 11. PMID: 22496271.

Buchi F, Spinelli E, Masala E, Gozzini A, Sanna A, Bosi A, Ferrari G, Santini V. Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine. *Leuk Res.* 2012 May;36(5):607-18. doi: 10.1016/j.leukres.2011.11.024. Epub 2012 Jan 9. PMID: 22230298.

Santini V. The quest for the perfect MDS scoring system. *Leuk Res.* 2012 Feb;36(2):125-6. doi: 10.1016/j.leukres.2011.10.026. Epub 2011 Dec 10. PMID: 22154763.

Platzbecker U, Santini V, Mufti GJ, Haferlach C, Maciejewski JP, Park S, Solé F, van de Loosdrecht AA, Haase D. Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): consensus statements and report from an expert workshop. *Leuk Res.* 2012 Mar;36(3):264-70. doi: 10.1016/j.leukres.2011.11.005. Epub 2011 Dec 3. PMID: 22137318.

Santini V. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes. *Oncologist.* 2011;16 Suppl 3:35-42. doi: 10.1634/theoncologist.2011-S3-35. PMID: 21930833.

Santini V, Girelli D, Sanna A, Martinelli N, Duca L, Campostrini N, Cortelezzi A, Corbella M, Bosi A, Reda G, Olivieri O, Cappellini MD. Hcpidin levels and their determinants in different types of myelodysplastic syndromes. *PLoS One.* 2011;6(8):e23109. doi: 10.1371/journal.pone.0023109. Epub 2011 Aug 19. PMID: 21886780; PMCID: PMC3158762.

Voso MT, Fabiani E, Piciocchi A, Matteucci C, Brandimarte L, Finelli C, Pogliani E, Angelucci E, Fioritoni G, Musto P, Greco M, Criscuolo M, Fianchi L, Vignetti M, Santini V, Hohaus S, Mecucci C, Leone G. Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine. *Leukemia.* 2011 Dec;25(12):1910-3. doi: 10.1038/leu.2011.170. Epub 2011 Jul 15. PMID: 21760590.

Latagliata R, Breccia M, Castagnetti F, Stagno F, Luciano L, Gozzini A, Ulisciani S, Cavazzini F, Annunziata M, Sorà F, Rossi AR, Pregnò P, Montefusco E, Abruzzese E, Crisà E, Musto P, Tiribelli M, Binotto G, Occhini U, Feo C, Vigneri P, Santini V, Fava C, Rosti G, Alimena G. Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients

resistant/intolerant to imatinib. *Leuk Res.* 2011 Sep;35(9):1164-9. doi: 10.1016/j.leukres.2011.05.015. Epub 2011 Jun 25. PMID: 21705080.

Breccia M, Latagliata R, Stagno F, Luciano L, Gozzini A, Castagnetti F, Fava C, Cavazzini F, Annunziata M, Russo Rossi A, Pregno P, Abruzzese E, Vigneri P, Rege-Cambrin G, Sica S, Pane F, Santini V, Specchia G, Rosti G, Alimena G. Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. *Haematologica.* 2011 Oct;96(10):1457-61. doi: 10.3324/haematol.2011.041251. Epub 2011 Jun 17. PMID: 21685471; PMCID: PMC3186306.

Silverman LR, Fenaux P, Mufti GJ, Santini V, Hellström-Lindberg E, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. *Cancer.* 2011 Jun 15;117(12):2697-702. doi: 10.1002/cncr.25774. Epub 2011 Jan 10. PMID: 21656747; PMCID: PMC400012.

Breccia M, Stagno F, Gozzini A, Abruzzese E, Latagliata R, Rossi AR, Sorà F, Porrini R, Vigneri P, Trawinska M, Montefusco E, Sica S, Specchia G, Santini V, Alimena G. Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors. *Am J Hematol.* 2011 Jun;86(6):523-5. doi: 10.1002/ajh.22020. PMID: 21594891.

Visani G, Breccia M, Montefusco E, Morra E, Santini V, Isidori A. The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply). *Haematologica.* 2011 Apr;96(4):e23-4; author reply e25. doi: 10.3324/haematol.2011.041319. PMID: 21454871; PMCID:

PMC3069247.

Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, Nagler A, Della Casa CM, Morra E, Abruzzese E, D'Emilio A, Stagno F, le Coutre P, Hurtado-Monroy R, Santini V, Martino B, Pane F, Piccin A, Giraldo P, Assouline S, Durosini MA, Leeksa O, Pogliani EM, Puttini M, Jang E, Reiffers J, Piazza R, Valsecchi MG, Kim DW. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. *J Natl Cancer Inst.* 2011 Apr 6;103(7):553-61. doi: 10.1093/jnci/djr060. Epub 2011 Mar 21. Erratum in: *J Natl Cancer Inst.* 2016 Sep;108(9). pii: djw211. doi: 10.1093/jnci/djw211. Piazza, Rocco [added]. PMID: 21422402.

Buchi F, Pastorelli R, Ferrari G, Spinelli E, Gozzini A, Sassolini F, Bosi A, Tombaccini D, Santini V. Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid. *Leuk Res.* 2011 Jul;35(7):921-31. doi: 10.1016/j.leukres.2011.01.033. Epub 2011 Mar 5. PMID: 21382639.

Visani G, Breccia M, Gozzini A, Specchia G, Montefusco E, Morra E, Annunziata M, Camera A, Cavazzini F, Stagno F, Pregno P, Usala E, Santini V, Piccaluga PP, Isidori A. Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. *Am J Hematol.* 2010 Dec;85(12):960-3. doi: 10.1002/ajh.21871. PMID: 21069865.

Fenaux P, Bowen D, Gattermann N, Hellström-Lindberg E, Hofmann WK, Pfeilstöcker M, Sanz G, Santini V. Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. *Leuk Res.* 2010 Nov;34(11):1410-6. doi: 10.1016/j.leukres.2010.05.021. Epub 2010 Jul 6. PMID:

20609474.

Seymour JF, Fenaux P, Silverman LR, Mufti GJ, Hellström-Lindberg E, Santini V, List AF, Gore SD, Backstrom J, McKenzie D, Beach CL. Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes. *Crit Rev Oncol Hematol*. 2010 Dec;76(3):218-27. doi: 10.1016/j.critrevonc.2010.04.005. Epub 2010 May 6. PMID: 20451404; PMCID: PMC4000027.

Santini V, Fenaux P, Mufti GJ, Hellström-Lindberg E, Silverman LR, List A, Gore SD, Seymour JF, Backstrom J, Beach CL. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. *Eur J Haematol*. 2010 Aug;85(2):130-8. doi: 10.1111/j.1600-0609.2010.01456.x. Epub 2010 Apr 12. PMID: 20394651; PMCID: PMC4000014.

Musto P, Maurillo L, Spagnoli A, Gozzini A, Rivellini F, Lunghi M, Villani O, Aloe-Spiriti MA, Venditti A, Santini V; Ad Hoc Italian Cooperative Study Group on Azacitidine in Myelodysplastic Syndromes Acute Leukemias. Azacitidine for the treatment of lower risk myelodysplastic syndromes: a retrospective study of 74 patients enrolled in an Italian named patient program. *Cancer*. 2010 Mar 15;116(6):1485-94. doi: 10.1002/cncr.24894. PMID: 20151429.

Santini V, Alessandrino PE, Angelucci E, Barosi G, Billio A, Di Maio M, Finelli C, Locatelli F, Marchetti M, Morra E, Musto P, Visani G, Tura S; Italian Society of Hematology. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. *Leuk Res*. 2010 Dec;34(12):1576-88. doi: 10.1016/j.leukres.2010.01.018. Epub 2010 Feb 11. PMID: 20149927.

Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing

U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. *J Clin Oncol*. 2010 Feb 1;28(4):562-9. doi: 10.1200/JCO.2009.23.8329. Epub 2009 Dec 21. PMID: 20026804.

Santini V. Azacitidine in lower-risk myelodysplastic syndromes. *Leuk Res*. 2009 Dec;33 Suppl 2:S22-6. doi: 10.1016/S0145-2126(09)70230-9. PMID: 20004794.

Voso MT, Santini V, Finelli C, Musto P, Pogliani E, Angelucci E, Fioritoni G, Alimena G, Maurillo L, Cortelezzi A, Buccisano F, Gobbi M, Borin L, Di Tucci A, Zini G, Petti MC, Martinelli G, Fabiani E, Fazi P, Vignetti M, Piciocchi A, Liso V, Amadori S, Leone G. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. *Clin Cancer Res*. 2009 Aug 1;15(15):5002-7. doi: 10.1158/1078-0432.CCR-09-0494. Epub 2009 Jul 28. PMID: 19638460.

Santini V. Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes. *Expert Rev Hematol*. 2009 Apr;2(2):121-7. doi: 10.1586/ehm.09.6. PMID: 21083445.

Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Müller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA; IRIS Investigators. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. *Leukemia*. 2009 Jun;23(6):1054-61. doi: 10.1038/leu.2009.38. Epub 2009 Mar 12. Erratum in: *Leukemia*. 2010 May;24(5):1102. PMID: 19282833.

Santini V. Is survival enough for myelodysplastic syndromes? *Leuk Res*. 2009 Aug;33(8):1017-8. doi: 10.1016/j.leukres.2009.02.001. Epub 2009 Mar 5. PMID:

19268362.

Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *Lancet Oncol.* 2009 Mar;*10*(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb 21. PMID: 19230772; PMCID: PMC4086808.

Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M, Krahnke T, Cortes J, Druker BJ; International Randomized Study of Interferon and ST1571 (IRIS) Investigators. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. *Cancer.* 2009 Feb 1;*115*(3):551-60. doi: 10.1002/cncr.24066. Erratum in: *Cancer.* 2010 Aug 1;*116*(15):3750. Santini, Valeria [added]. PMID: 19117345; PMCID: PMC4445370.

Bennett JM; MDS Foundation's Working Group on Transfusional Iron Overload. Consensus statement on iron overload in myelodysplastic syndromes. *Am J Hematol.* 2008 Nov;*83*(11):858-61. doi: 10.1002/ajh.21269. PMID: 18767130.

Santini V, Gozzini A, Bosi A. Treatment options in myelodysplastic syndromes: a new frontier. *J Chemother.* 2008 Jun;*20*(3):291-6. doi: 10.1179/joc.2008.20.3.291. PMID: 18606581.

Ciulli S, Leoni F, Casini C, Breschi C, Santini V, Bosi A. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. *Br J Haematol.* 2008 Jun;*141*(6):814-9. doi: 10.1111/j.1365-2141.2008.07147.x. Epub 2008 Apr 10. PMID:

18410447.

Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, Ponziani V, Tozzi L, Pieri L, Santini V, Bosi A, Vannucchi AM; Myeloproliferative Disorders Research Consortium (MPD-RC). Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. *Haematologica*. 2008 Jan;93(1):41-8. doi: 10.3324/haematol.11653. PMID: 18166784.

Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LB. Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update. *Ecancermedicalscience*. 2008; 2:121. doi: 10.3332/ecancer.2008.121. Epub 2008 Dec 10. PMID: 22275991; PMCID: PMC3234073.

Silverman LR, Fenaux P, Mufti GJ, Santini V, Hellström-Lindberg E, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF, Backstrom J, McKenzie D, Beach CL. The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update. *Ecancermedicalscience*. 2008;2:118. doi: 10.3332/ecancer.2008.118. Epub 2008 Dec 8. PMID: 22275990; PMCID: PMC3234059.

Antonioli E, Guglielmelli P, Poli G, Santini V, Bosi A, Vannucchi AM. Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance. *Blood*. 2007 Dec 15;110(13):4620-1. doi: 10.1182/blood-2007-07-103267. PMID: 18056850.

Barbetti V, Gozzini A, Rovida E, Morandi A, Spinelli E, Fossati G, Mascagni P, Lübbert M, Dello Sbarba P, Santini V. Selective anti-leukaemic activity of

low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells. *Oncogene*. 2008 Mar 13;27(12):1767-78. doi: 10.1038/sj.onc.1210820. Epub 2007 Sep 24. PMID: 17891169.

Santini V, Gozzini A, Ferrari G. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. *Curr Drug Metab*. 2007 May;8(4):383-93. doi: 10.2174/138920007780655397. PMID: 17504226.

Santini V. A selective activity of DNMTi decitabine on AML1ETO positive cells? *Leuk Res*. 2007 Jun;31(6):741-2. doi: 10.1016/j.leukres.2006.12.010. Epub 2007 Jan 22. PMID: 17240447.

Ferrari G, Pastorelli R, Buchi F, Spinelli E, Gozzini A, Bosi A, Santini V. Comparative proteomic analysis of chronic myelogenous leukemia cells: inside the mechanism of imatinib resistance. *J Proteome Res*. 2007 Jan;6(1):367-75. doi: 10.1021/pr0603708. PMID: 17203980.

Rovida E, Gozzini A, Barbetti V, Giuntoli S, Santini V, Dello Sbarba P. The c-Jun-N-terminal-Kinase inhibitor SP600125 enhances the butyrate derivative D1-induced apoptosis via caspase 8 activation in Kasumi 1 t(8;21) acute myeloid leukaemia cells. *Br J Haematol*. 2006 Dec;135(5):653-9. doi: 10.1111/j.1365-2141.2006.06365.x. Epub 2006 Oct 19. PMID: 17054427.

Santoro L, Santini V, Lollo SD, Valeri A, Colagrande S. Hemolymphangiomas of the spleen: imaging features. *J Comput Assist Tomogr*. 2005 Nov-Dec;29(6):831-3. doi: 10.1097/01.rct.0000178713.40170.73. PMID: 16272860.

Gozzini A, Santini V. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia

blasts. *Ann Hematol.* 2005 Dec;84 Suppl 1:54-60. doi: 10.1007/s00277-005-0006-z. PMID: 16228241.

Visani G, Isidori A, Grafone T, Tosi P, Santini V, Malagola M, Martinelli G, Piccaluga PP, Gaziev D, Ottaviani E, Sparaventi G, Tura S. No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response? *Leuk Lymphoma.* 2004 Jul;45(7):1361-4. doi: 10.1080/10428190310001653673. PMID: 15359633.

Galimberti S, Guerrini F, Palumbo GA, Consoli U, Fazzi R, Morabito F, Santini V, Petrini M. Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients. *Leuk Res.* 2004 Apr;28(4):367-72. doi: 10.1016/j.leukres.2003.09.002. PMID: 15109536.

Gozzini A, Rovida E, Dello Sbarba P, Galimberti S, Santini V. Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts. *Cancer Res.* 2003 Dec 15;63(24):8955-61. Erratum in: *Cancer Res.* 2004 May 15;;64(14):3725. Galimbert S [corrected to Galimberti S]. PMID: 14695213.

Monici M, Agati G, Fusi F, Pratesi R, Paglierani M, Santini V, Bernabei PA. Dependence of leukemic cell autofluorescence patterns on the degree of differentiation. *Photochem Photobiol Sci.* 2003 Oct;2(10):981-7. doi: 10.1039/b306276g. PMID: 14606752.

Galimberti S, Rossi A, Palumbo GA, Morabito F, Guerrini F, Vincelli I, Fazzi R, Santini V, Petrini M. FLT3 mutations do not influence MDR-1 gene expression in acute myeloid leukemia. *Anticancer Res.* 2003 Jul-Aug;23(4):3419-26. PMID: 12926083.

Biscardi M, Caporale R, Pagliai G, Leoni F, Bernabei P, Santini V, Ciolli S, Grossi A. In vitro antileukemic effect of a new anthracycline analogue, MEN 11079. *Leuk Res.* 2003 Dec;27(12):1125-34. doi: 10.1016/s0145-2126(03)00105-x. PMID: 12921951.

Santini V, Scappini B, Indik ZK, Gozzini A, Ferrini PR, Schreiber AD. The carboxy-terminal region of the granulocyte colony-stimulating factor receptor transduces a phagocytic signal. *Blood.* 2003 Jun 1;101(11):4615-22. doi: 10.1182/blood-2002-07-2271. Epub 2003 Feb 13. PMID: 12586631.

Santini V, Scappini B, Grossi A, Gozzini A, Bonsi L, Pagliai G, Rossi Ferrini P, Bagnara GP. Lyn kinase is activated following thrombopoietin stimulation of the megakaryocytic cell line B1647. *Haematologica.* 2002 Dec;87(12):1242-7. PMID: 12495897.

Grossi A, Musto P, Santini V, Balestri F, Fabbri A, Falcone A, Sanpaolo G. Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes. *Haematologica.* 2002 Mar;87(3):322-3. PMID: 11869946.

Kantarjian HM, Talpaz M, Santini V, Murgu A, Cheson B, O'Brien SM. Homoharringtonine: history, current research, and future direction. *Cancer.* 2001 Sep 15;92(6):1591-605. doi: 10.1002/1097-0142(20010915)92:6<1591::aid-cncr1485>3.0.co;2-u. PMID: 11745238.

Santini V, Gozzini A, Scappini B, Grossi A, Rossi Ferrini P. Searching for the magic bullet against cancer: the butyrate saga. *Leuk Lymphoma.* 2001 Jul;42(3):275-89. doi: 10.3109/10428190109064584. PMID: 11699392.

Santini V. Amifostine: chemotherapeutic and radiotherapeutic protective effects. *Expert Opin Pharmacother.* 2001 Mar;2(3):479-89. doi:

10.1517/14656566.2.3.479. PMID: 11336600.

Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. *Ann Intern Med.* 2001 Apr 3;134(7):573-86. doi: 10.7326/0003-4819-134-7-200104030-00011. PMID: 11281740.

Leoni F, Ciolli S, Nozzoli C, Santini V, Fanci R, Rossi Ferrini P. Fludarabine, cytarabine and topotecan (FLAT) as induction therapy for acute myeloid leukemia in the elderly: a preliminary report. *Haematologica.* 2001 Jan;86(1):104. PMID: 11146581.

Grossi A, Fabbri A, Santini V, Leoni F, Nozzoli C, Longo G, Pagliai G, Ciolli S, Rossi Ferrini P. Amifostine in the treatment of low-risk myelodysplastic syndromes. *Haematologica.* 2000 Apr;85(4):367-71. PMID: 10756361.

Giles FJ, O'Brien SM, Santini V, Gandhi V, Plunkett W, Seymour JF, Robertson LE, Kantarjian HM, Keating MJ. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study. *Leuk Lymphoma.* 1999 Dec;36(1-2):57-65. doi: 10.3109/10428199909145949. PMID: 10613450.

Santini V, Giles FJ. The potential of amifostine: from cytoprotectant to therapeutic agent. *Haematologica.* 1999 Nov;84(11):1035-42. PMID: 10553165.

Alterini R, Rigacci L, Stefanacci S, Innocenti F, Santini V, Carrai V, Rossi Ferrini P. Immunohistochemistry applied to the study of bone marrow Gaucher's cells: a case report. *Eur J Histochem.* 1999;43(3):235-9. PMID: 10563256.

Santini V, Gozzini A, Scappini B, Caporale R, Zoccolante A, Rigacci L,

Gelardi E, Grossi A, Alterini R, Ferrini PR. Induction of apoptosis by monosaccharide butyrate stable derivatives in chronic lymphocytic leukemia cells. *Haematologica*. 1999 Oct;84(10):897-904. PMID: 10509037.

Bernabei PA, Landini I, Bartolozzi B, Banchelli I, Degli Innocenti o Nocentini A, Santini V, Ematologia UO. Activity of vinorelbine on B-chronic lymphocytic leukemia cells in vitro. *Adv Exp Med Biol*. 1999;457:473-6. doi: 10.1007/978-1-4615-4811-9_51. PMID: 10500824.

Monici M, Fusi F, Mazzinghi P, Degli Innocenti o Nocentini A, Landini I, Banchelli I, Bartolozzi B, Santini V, Bernabei PA. Natural fluorescence imaging of leukemic cells for studying uptake and retention of anthracyclines. *Adv Exp Med Biol*. 1999;457:89-94. doi: 10.1007/978-1-4615-4811-9_11. PMID: 10500784.

Santini V, Gozzini A, Scappini B, Rossi Ferrini P. Maturation and apoptosis of primary human acute myeloblastic leukemia cells are determined by TNF-alpha exclusively through CD120A stimulation. *Haematologica*. 1999 Apr;84(4):291-7. PMID: 10190941.

Grossi A, Nozzoli C, Gheri R, Santini V, Marrani C, Zoccolante A, Ferrini PR. Pure red cell aplasia in autoimmune polyglandular syndrome with T lymphocytosis. *Haematologica*. 1998 Nov;83(11):1043-5. PMID: 9864928.

Pouillart P, Douillet O, Scappini B, Gozzini A, Santini V, Grossi A, Pagliai G, Strippoli P, Rigacci L, Ronco G, Villa P. Regioselective synthesis and biological profiling of butyric and phenylalkylcarboxylic esters derivated from D-mannose and xylitol: influence of alkyl chain length on acute toxicity. *Eur J Pharm Sci*. 1999 Jan;7(2):93-106. doi: 10.1016/s0928-0987(98)00011-6. PMID: 9845786.

Linari S, Vannucchi AM, Ciolli S, Leoni F, Caporale R, Grossi A, Pagliai G, Santini V, Paoletti F, Ferrini PR. Coexpression of erythroid and megakaryocytic genes in acute erythroblastic (FAB M6) and megakaryoblastic (FAB M7) leukaemias. *Br J Haematol.* 1998 Sep;102(5):1335-7. doi: 10.1046/j.1365-2141.1998.00904.x. PMID: 9753066.

Santini V, Ferrini PR. Differentiation therapy of myelodysplastic syndromes: fact or fiction? *Br J Haematol.* 1998 Sep;102(5):1124-38. doi: 10.1046/j.1365-2141.1998.00881.x. PMID: 9753034.

Santini V, Scappini B, Gozzini A, Grossi A, Villa P, Ronco G, Douillet O, Pouillart P, Bernabei PA, Rossi Ferrini P. Butyrate-stable monosaccharide derivatives induce maturation and apoptosis in human acute myeloid leukaemia cells. *Br J Haematol.* 1998 Jun;101(3):529-38. doi: 10.1046/j.1365-2141.1998.00727.x. PMID: 9633898.

de Koning JP, Soede-Bobok AA, Schelen AM, Smith L, van Leeuwen D, Santini V, Burgering BM, Bos JL, Lowenberg B, Touw IP. Proliferation signaling and activation of Shc, p21Ras, and Myc via tyrosine 764 of human granulocyte colony-stimulating factor receptor. *Blood.* 1998 Mar 15;91(6):1924-33. PMID: 9490675.

Gaidano G, Pastore C, Santini V, Nomdedeu J, Gamberi B, Capello D, Vischia F, Resegotti L, Mazza U, Ferrini PR, Lo Coco F, Saglio G. Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia. *Genes Chromosomes Cancer.* 1997 Aug;19(4):250-5. PMID: 9258660.

Santini V, Bernabei A, Gozzini A, Scappini B, Zoccolante A, D'Ippolito G, Figuccia M, Ferrini PR. Apoptotic and antiproliferative effects of gemcitabine and gemcitabine plus Ara-C on blast cells from patients with blast crisis chronic myeloproliferative disorders. *Haematologica.* 1997 Jan-Feb;82(1):11-5.

PMID: 9172997.

Santini V, Zoccolante A, Bosi A, Guidi S, Saccardi R, Vannucchi AM, Martinazzo G, Bernabei PA, Ferrini PR. Detection of bcr/abl transcripts by RT-PCR and their colorimetric evaluation in chronic myeloid leukemia patients receiving allogeneic bone marrow transplantation. *Haematologica*. 1996 May-Jun;81(3):201-7. PMID: 8767524.

Santini V, D'Ippolito G, Bernabei PA, Zoccolante A, Ermini A, Rossi-Ferrini P. Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60: direct comparison of cytotoxicity and cellular Ara-C uptake enhancement. *Leuk Res*. 1996 Jan;20(1):37-45. doi: 10.1016/0145-2126(95)00106-9. PMID: 8632676.

Quattrone A, Papucci L, Santini V, Schiavone N, Noferini D, Calastretti A, Copreni E, Morelli S, Rossi Ferrini PL, Nicolini A, et al. Quantitation of bcl-2 oncogene in cultured lymphoma/leukemia cell lines and in primary leukemia B-cells by a highly sensitive RT-PCR method. *Haematologica*. 1995 Nov-Dec;80(6):495-504. PMID: 8647513.

Santini V, Lamberts SW, Krenning EP, Backx B, Löwenberg B. Somatostatin and its cyclic octapeptide analog SMS 201-995 as inhibitors of proliferation of human acute lymphoblastic and acute myeloid leukemia. *Leuk Res*. 1995 Oct;19(10):707-12. doi: 10.1016/0145-2126(95)00041-I. PMID: 7500646.

Orlandini SZ, Formigli L, Benvenuti S, Lasagni L, Franchi A, Masi L, Bernabei PA, Santini V, Brandi ML. Functional and structural interactions between osteoblastic and preosteoclastic cells in vitro. *Cell Tissue Res*. 1995 Jul;281(1):33-42. doi: 10.1007/BF00307956. PMID: 7621525.

Löwenberg B, van Putten WL, Touw IP, Delwel R, Santini V. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. *N Engl J Med*. 1993 Mar 4;328(9):614-9. doi: 10.1056/NEJM199303043280904. PMID: 8429853.

Rossi Ferrini P, Santini V, Ciolli S, Grossi A, Leoni F, Rafanelli D, Vannucchi AM. The role of haematopoietic growth factors in the treatment of myelodysplastic syndromes. *Hematol Oncol*. 1993;11 Suppl 1:32-5. PMID: 7683622.

Colombat P, Santini V, Delwel R, Krefft J, Bredmond JL, Löwenberg B. Primary human acute myeloblastic leukaemia: an analysis of in vitro granulocytic maturation following stimulation with retinoic acid and G-CSF. *Br J Haematol*. 1991 Nov;79(3):382-9. doi: 10.1111/j.1365-2141.1991.tb08045.x. PMID: 1721525.

Bergamaschi G, Cazzola M, Rosti V, Carlo-Stella C, Santini V, Ponchio L, Peverali FA, Della Valle G, Rossi Ferrini P, Ascari E. Tumor necrosis factor alpha modulates the messenger RNA expression of hematopoietic growth factor genes in fresh blast cells from patients with acute myeloblastic leukemia. *Leukemia*. 1991 Oct;5(10):886-91. PMID: 1961022.

Bernabei PA, Ermini A, Santini S, Santini V, Fossombroni V, Rossi Ferrini P. Effect of (dl)-5-methyltetrahydrofolate on acute non-lymphocytic leukemia cells in primary culture. *J Chemother*. 1991 Aug;3(4):255-9. doi: 10.1080/1120009x.1991.11739101. PMID: 1779261.

Touw I, Donath J, Pouwels K, van Buitenen C, Schipper P, Santini V, Hagemeyer A, Löwenberg B, Delwel R. Acute myeloid leukemias with chromosomal abnormalities involving the 21q22 region identified by their in vitro responsiveness to interleukin-5. *Leukemia*. 1991 Aug;5(8):687-92. PMID: 1715959.

Santini V, Colombat P, Delwel R, van Gurp R, Touw I, Löwenberg B. Induction of granulocytic maturation in acute myeloid leukemia by G-CSF and retinoic acid. *Leuk Res.* 1991;15(5):341-50. doi: 10.1016/0145-2126(91)90009-i. PMID: 1710746.

Dal Pozzo O, Santini V, Saccardi R, Bernabei PA, Rossi Ferrini P. Assessment of PTT 119 activity on acute nonlymphoblastic leukemia cells by [3H]-thymidine uptake inhibition and cluster analysis. *Haematologica.* 1990 Jan-Feb;75(1):50-3. PMID: 2338287.

Santini V, Nooter K, Delwel R, Löwenberg B. Susceptibility of acute myeloid leukemia (AML) cells from clinically resistant and sensitive patients to daunomycin (DNR): assessment in vitro after stimulation with colony stimulating factors (CSFs). *Leuk Res.* 1990;14(4):377-80. doi: 10.1016/0145-2126(90)90166-7. PMID: 2332990.

Bernabei PA, Mini E, Gattei V, Agostino FC, Bezzini R, Saccardi R, Santini V, Coronello M, Mazzei T, Rossi Ferrini P. Induction of differentiation of HL-60 cells along the monocytic pathway by 5-methyltetrahydrofolate. *J Chemother.* 1989 Dec;1(6):359-64. doi: 10.1080/1120009x.1989.11738923. PMID: 2614501.

Dal Pozzo O, Bernabei PA, Santini V, Saccardi R, Santini S, Rossi Ferrini P. A comparison of two assays for the in vitro chemosensitivity testing of human acute non-lymphoblastic leukemia cells. *J Chemother.* 1989 Oct;1(5):318-23. doi: 10.1080/1120009x.1989.11738915. PMID: 2585033.

Santini V, Bernabei PA, Silvestro L, Dal Pozzo O, Bezzini R, Viano I, Gattei V, Saccardi R, Ferrini PR. In vitro chemosensitivity testing of leukemic cells: prediction of response to chemotherapy in patients with acute non-lymphocytic leukemia. *Hematol Oncol.* 1989 Jul-Aug;7(4):287-93. doi:

10.1002/hon.2900070405. PMID: 2737608.

Bernabei PA, Santini V, Silvestro L, Dal Pozzo O, Bezzini R, Viano I, Gattei V, Saccardi R, Rossi Ferrini P. In vitro chemosensitivity testing of leukemic cells: development of a semiautomated colorimetric assay. *Hematol Oncol.* 1989 May-Jun;7(3):243-53. doi: 10.1002/hon.2900070307. PMID: 2707746.

Bernabei PA, Rombolà G, Saccardi R, Bezzini R, Santini V, Pifferi C, Gattei V, Ferrini PR. Scheduling-dependent interaction for the combination of cytosine arabinoside and daunorubicin on HL-60 cells. *Haematologica.* 1988 Nov-Dec;73(6):466-70. PMID: 3148508.

Bernabei PA, Santini V, Dal Pozzo O, Bezzini R, Gattei V, Saccardi R, Rombolà G, Ferrini PR. Clonogenic growth of acute non-lymphocytic leukemia cells in serum-free medium. *Experientia.* 1988 Oct 15;44(10):903-6. doi: 10.1007/BF01941197. PMID: 3181378.

Bernabei PA, Agostino FC, Bezzini R, Saccardi R, Gattei V, Santini V, Casini M, Rossi Ferrini P. Proliferation and cell loss of human leukemic cell subpopulations in liquid culture. *Experientia.* 1988 Mar 15;44(3):245-7.

In fede ,

Valeria Santini

Firenze